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REGULATORY BARRIERS WHEN IMPLEMENTING E-PRESCRIBING 
OF CONTROLLED SUBSTANCES: COULD MODEL LANGUAGE BE 
THE SOLUTION? 
Arguably nothing in our health-driven society permeates our everyday 
life more than prescription drugs.  Evidence of this comes from all avenues 
of the prescription drug industry.  Prescription drug direct-to-consumer 
advertising is a multi-billion dollar market.1  Prescription drug revenues 
totaled $300.3 billion dollars in 2009,2  and over 3.6 billion prescriptions 
were dispensed.3  In light of these trends, it is no surprise that prescription 
drug markets have been pushed to enhance delivery of medications from 
the physician to patient.  This article will focus on the relatively new realm of 
electronic prescribing (“e-prescribing”) and the effect new Drug Enforcement 
Agency (“DEA”) regulations4 will have on the practical implementation and 
delivery of prescription medications. 
Health information technology (“HIT”), electronic health records 
(“EHR”), and e-prescribing are some of the flagships of healthcare reform.5  
However, this isn’t a new phenomenon, EHR and e-prescribing initiatives 
were implemented prior to the Clinton Administration within the Department 
of Veterans Affairs’ health system, under the VIST-A program.6  VIST-A was 
 
 1. Theresa Howard, Push Is on to End Prescription Drug Ads Targeting Consumers, USA 
Today, (Aug. 10, 2009, 11:10 AM), http://www.usatoday.com/money/advertising/adtrack/ 
2009-08-09-adtrack-prescription-drug-ads_N.htm. 
 2. Bill Berkrot, U.S. Prescription Drug Sales Hit $300 bln in 2009, REUTERS (Apr. 1, 2010, 
1:34 PM), http://www.reuters.com/article/idUSTRE6303CU20100401. 
 3. Id. 
 4. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236 
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311). 
 5. Daniel J. Gilman & James C. Cooper, There Is a Time to Keep Silent and a Time to 
Speak, the Hard Part Is Knowing Which Is Which: Striking the Balance Between Privacy 
Protection and the Flow of Health Care Information, 16 MICH. TELECOMM. & TECH. L. REV. 279, 
280, 286, 288 (2010); see also ATTILA HERTELENDY ET AL., AM. HEALTH INFO. MGMT. ASS’N 
(AHIMA), THE IMPLICATIONS OF HEALTH REFORM FOR HEALTH INFORMATION AND ELECTRONIC 
HEALTH RECORD IMPLEMENTATION EFFORTS 1 (2010), available at http://perspectives. 
ahima.org/PDF/Summer_2010/Implications_of_Health_Reform/Implications_of_Health_Re 
form_on_Health_Information_final.pdf. 
 6. DOUGLAS GOLDSTEIN ET AL., Case Studies of VistA Implementation—United States and 
International, in MEDICAL INFORMATICS 20/20, at 223, 226, 263 (2007), available at 
http://www.jblearning.com/samples/0763739251/39251_CH09_223_284.pdf; see also 
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the first major venture into the realm of EHR and e-prescribing, with the 
computerization of Veteran Affairs’ health records.7  The reach of e-
prescribing is realizing new levels of integration with the promulgation of the 
DEA’s new rule regulating e-prescribing of controlled substances.8  In March 
2010, the DEA issued rules allowing e-prescribing of controlled substances 
by all eligible, DEA-approved prescribers.9 
I.  E-PRESCRIBING EXAMINED 
Before delving into the barriers of implementation and the potential 
solutions, an examination of e-prescribing is warranted.  E-prescribing is 
defined as the transmission of prescription information through electronic 
media between the prescriber, pharmacy, pharmacy benefit manager, 
and/or health insurance plan.10  E-prescribing can be a two-way or a multi-
step transmission process.11  At its core, the eligible prescriber types a 
prescription and sends it electronically (not by fax but via a closed secured 
internet network) to a participating pharmacy.12  This information may go 
directly to a pharmacy or it may first be redirected to a health plan or 
managed care entity, such as a pharmacy benefit manager (“PBM”), for 
insurance approval.13  Prescribers now have the option of sending electronic 
 
June M. Sullivan, Recent Development and Future Trends in Electronic Medical and Personal 
Health Records, HEALTH LAW., Jan. 2007, at 16, 17. 
 7. GOLDSTEIN ET AL., supra note 6, at 226, 227, 263. 
 8. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,236. 
 9. The prescriber must meet all the formal requirements of the rule which includes a DEA 
registration number in good standing with the DEA.  Id. at 16,313. 
 10. EHEALTH INITIATIVE, A CLINICIAN’S GUIDE TO ELECTRONIC PRESCRIBING 1 (2008), 
available at http://www.ama-assn.org/ama1/pub/upload/mm/472/electronic-e-prescrib 
ing.pdf; see also NAT’L GOVERNORS ASS’N, ACCELERATING THE ADOPTION OF ELECTRONIC 
PRESCRIBING 1 (2009), available at http://www.nga.org/files/live/sites/NGA/files/pdf/0907E 
PRESCRIBING.PDF.  The National Governors Association “electronic prescribing, or e-
prescribing, is computer-based electronic generation and transmission of a prescription.”  Id. 
at 2. 
 11. CAL. HEALTHCARE FOUND., E-PRESCRIBING 21 (2001), available at http://www.ch 
cf.org/~/media/MEDIA%20LIBRARY%20Files/PDF/E/PDF%20EPrescribing.pdf. 
 12. Id. at 5; see also EHEALTH INITIATIVE, supra note 10, at 7, 25; see also SIEMENS, E-
PRESCRIBING: THE PATH TO PHYSICIAN ADOPTION OF HIT 6 (2009), available at http://www.medi 
cal.siemens.com/siemens/en_INT/rg_marcom_FBAs/images/News/2010_01_HIT/EPrescribe
whitepaperA91339721v3.pdf. 
 13. CAL. HEALTHCARE FOUND., supra note 11, at 20.  Many e-prescribing initiatives can 
involve the insurance and formulary process to streamline insurance eligibility and coverage 
problems.  EHEALTH INITIATIVE, supra note 11, at 1, 4.  However, it is common for the e-
prescribing relationship to be executed directly to retail pharmacies where a pharmacist and 
pharmacy technician handle insurance processing, prior authorizations, or any other insurance 
coverage/formulary issues.  CAL. HEALTHCARE FOUND., supra note 11, at 20. 
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prescriptions via wireless devices such as secure PDAs or cellular phones.14  
Pharmacies in turn receive the information through their closed pharmacy 
network and computer dispensing software that performs dispensing and 
screening functions.15  Providers have two general approaches for 
implementing e-prescribing in their environment either: (1) stand-alone 
systems; or (2) integrated EHR systems with e-prescribing capabilities.16  The 
latter involves a complete electronic overhaul of medical records including 
medical charting, lab results, billing information, and e-prescribing.17  The 
stand-alone system is a separate software program that allows physicians to 
use traditional hospital resources in conjunction with a separate e-
prescribing software component.18 
E-prescribing has been scientifically studied and statistically proven to 
bring a number of benefits to the practice of medicine and pharmacy.19  E-
prescribing reduces medication errors,20 and establishes a system to warn 
physicians of drug interactions and contraindications.21  E-prescribing can 
economize a physician’s practice if properly integrated into the workflow.22  
 
 14. CAL. HEALTHCARE FOUND., supra note 11, at 30. 
 15. Most major pharmacy software companies include e-prescribing software that 
integrates into an existing pharmacy system.  Surescripts Certified Pharmacy Software, 
SURESCRIPTS, http://www.surescripts.com/connect-to-surescripts/pharmacy-software.aspx (last 
visited Nov. 8, 2011). 
 16. EHEALTH INITIATIVE, supra note 10, at 2. 
 17. Id. 
 18. Id. 
 19. Gordon D. Schiff & T. Donald Rucker, Computerized Prescribing: Building the 
Electronic Infrastructure for Better Medication Usage, 279 JAMA 1024, 1024 (1998).  
“According to the Center for Information Technology Leadership, use of e-prescribing and 
advanced decision-support capabilities could help prevent 130,000 medication errors 
annually.” NAT’L GOVERNORS ASS’N, supra note 10, at 4. 
 20. David W. Bates et al., The Impact of Computerized Physician Order Entry on 
Medication Error Prevention, 6 JAMA 313, 319 (1999).  Clinical decision support systems in 
e-prescribing software can perform checks against the patient’s current medications for drug 
interactions, drug-allergy interactions, diagnoses, body weight, age, and correct dosing. 
EHEALTH INITIATIVE, supra note 10, at 3 
 21. EHEALTH INITIATIVE, supra note 10, at 3.  It alerts prescribers to contraindications, 
adverse reactions, and duplicate therapy by using drug reference information, such as the 
Physician’s Desk Reference (PDR) or Wolters Kluwer Health, Facts and Comparison.  Id.; Facts 
& Comparisons: About Us, WOLTERS KLUWER HEALTH, http://www.factsandcomparisons.com/a 
bout-us.aspx (last visited Nov. 8, 2011). 
 22. Dereck L. Hunt et al., Effects of Computer-Based Clinical Decision Support Systems on 
Physician Performance and Patient Outcomes: A Systematic Review, 280 JAMA 1339, 1344 
(1998); see also Amit X. Garg et al., Effects of Computerized Clinical Decision Support 
Systems on Practitioner Performance and Patient Outcomes: A Systematic Review, 293 JAMA 
1223, 1223 (2005). 
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E-prescribing also curbs illegible doctor’s scrawl,23 and misinterpreted oral 
orders for medication.24  Additionally, e-prescribing reduces time spent on 
the phone with pharmacies, insurers, and other health care providers and it 
streamlines the medication delivery process.25  E-prescribing has been 
shown to increase medication adherence and improve formulary 
management for patients.26  If these benefits are not enough evidence, the 
e-prescribing adoption rate speaks for itself.  Between 2008 and 2009 e-
prescribing levels grew 284%.27  All of these benefits culminated in the 
Institute of Medicine’s (“IOM”) recommendation that by 2010 “all 
prescribers should write, and all pharmacies should be able to receive, 
electronic prescriptions.”28 
Another major benefit to e-prescribing is the significant “buy-in” from 
the federal government.  Beyond the new DEA rule, there have been several 
initiatives to foster e-prescribing adoption.  The Medicare Modernization Act 
(“MMA”) established the Medicare Part D drug benefit through privatized 
insurance companies.29 With the Bush Administration’s urging, one 
 
 23. EHEALTH INITIATIVE, supra note 10, at 3; The Institute of Medicine (IOM) estimates 
doctor’s illegible handwriting kills thousands of people each year. Jeremy Caplan, Cause of 
Death: Sloppy Doctors, TIME (Jan. 15, 2007), http://www.time.com/time/health/article/ 
0,8599,1578074,00.html. 
 24. Many oral prescription orders over the phone can be misinterpreted from the doctor 
or doctor’s agent to the pharmacist or pharmacist technician.  EHEALTH INITIATIVE, supra note 
10, at 3. 
 25. Id.; CAL. HEALTH CARE FOUND., supra note 11, at 5; “Physicians and pharmacists 
spend up to 25% of their time clarifying prescription orders and processing renewal requests.”  
NAT’L GOVERNORS ASS’N, supra note 10, at 4.  The lost wages, time and productivity from 
these clarification duties may be limited by reducing potential communication failures.  Id. 
 26. “It is estimated that 20% of paper-based prescription orders go unfilled by the 
patient—at least in part due to the hassle of dropping off a paper prescription and waiting for 
it to be filled.”  EHEALTH INITIATIVE, supra note 10, at 4.  “By eliminating or reducing this wait, 
e-prescribing may help reduce the number of unfilled prescriptions.”  Id.  Additionally e-
prescribing allows health providers to track and analyze medication usage and efficacy.  NAT’L 
GOVERNORS ASS’N, supra note 10, at 4.  Beyond the medical community, private payors and 
self-insured employers recognize the benefits of e-prescribing and interoperable health 
records.  Larry S. Boress, An Extreme Makeover for the Employer’s House of Health Benefits, 
32 J. LEGAL MED. 51, 59 (2011). 
 27. SURESCRIPTS, ADVANCING HEALTHCARE IN AMERICA: 2009 NATIONAL PROGRESS REPORT 
ON E-PRESCRIBING, PLUS WHAT’S AHEAD IN 2010 AND BEYOND 6 (2010). 
 28. Robert Steinbrook, The (Slowly) Vanishing Prescription Pad, 359 NEW ENG. J. MED. 
115, 116 (2008); see also INST. OF MED., PREVENTING MEDICATION ERRORS: QUALITY CHASM 
SERIES 16 (2006). 
 29. This legislation provides seniors and individuals with disabilities with a prescription 
drug benefit, more choices with privatized insurers, and better benefits under Federal 
Medicare coverage.  See Medicare Prescription Drug Improvement and Modernization Act of 
2003, Pub. L. No. 108-173, § 101, 117 Stat. 2066, 2072 (codified as amended at 42 
U.S.C. § 1395w-101(a)(1)(B)(iii)). 
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provision of MMA required all insurance plans participating in the new 
prescription benefit must support e-prescribing.30  Although MMA did not 
mandate prescribers or pharmacies to accept electronic prescriptions,31 this 
insurance plan requirement was a step toward universal adoption of e-
prescribing and EHR utilization.  In 2008, Congress authorized the Center 
for Medicare and Medicaid Services (“CMS”) to implement a Physician 
Incentive Program32 under the federal statute, Medicine Improvements for 
Patients and Providers Act (“MIPPA”).33  The Physician Incentive Program34 
established by CMS offers financial incentives to providers who implement 
electronic health records with e-prescribing capabilities.35  One of the 
requirements under the program is that prescribers must “meaningfully use” 
e-prescribing with a “certified” electronic health record system.36  E-
 
 30. See id. § 101, 117 Stat. at 2087 (codified as amended at 42 U.S.C. § 1395w-
103(e)(2)(A)); see generally 42 U.S.C. §§ 1395w-101 to -154 (2006). 
 31. Lisette Hilton, Steady Progress in E-prescribing, AHIP COVERAGE (July/Aug. 2008), 
http://216.52.120.13/content/default.aspx?bc=31%7C130%7C136%7C24075%7C24080; 
see U.S. DEP’T OF HEALTH & HUMAN SERVS., MEDICARE PART D E-PRESCRIBING STANDARDS: EARLY 
ASSESSMENT SHOWS PARTIAL CONNECTIVITY 4 n.9 (2009), available at http://oig.hhs.gov/oei/re 
ports/oei-05-08-00320.pdf; see also Medicare Prescription Drug Improvement and 
Modernization Act § 101, 117 Stat. at 2087, 2089 (codified as amended at 42 U.S.C. § 
1395w-103(e)). 
 32. “[M]edicare Improvements for Patients and Providers Act of 2008 (MIPPA) authorizes 
a new and separate incentive program for eligible professionals who are successful electronic 
prescribers . . . .  This new incentive program . . . began on January 1, 2009 . . . .  To 
participate in the . . . eRx Incentive Program, individual eligible professionals must report on 
their adoption and use of a qualified eRx system by submitting claims information . . . on their 
Medicare Part B claims.”  Overview: Electronic Prescribing (eRx) Incentive Program, CTRS. FOR 
MEDICARE & MEDICAID SERVS., https://www.cms.gov/ERxIncentive/01_Overview.asp#TopOf 
Page (last visited Nov. 5, 2011) [hereinafter eRx Incentives].  To be considered for the 
incentive program and potentially qualify to earn a 2% incentive payment on each eRx claim, 
prescribers must report the eRx measure in at least 50% of the cases.  Id. 
 33. See Medicare Improvements for Patients and Providers Act (MIPPA) of 2008, Pub. L. 
No. 110-275, § 132, 122 Stat. 2494, 2527 (to be codified at 42 U.S.C. 1395w-4). 
 34. eRx Incentives, supra note 32.  But see Lindsey Getz, E-Prescribing Standards — More 
Clarity Needed, FOR THE RECORD, Apr. 26, 2010, at 14, 15. (“There are still many roadblocks 
in the way of more widespread adoption, perhaps the most significant being the confusion that 
continues to surround the process. . . . [T]he biggest problem currently seems to be a lack of 
understanding about what's expected . . . .”). 
 35. AM. MED. ASS’N, UNDERSTANDING THE BASICS OF MEDICARE’S ELECTRONIC PRESCRIBING 
INCENTIVE PROGRAM 1, available at http://www.ama-assn.org/assets/eprescribing/download 
able_resources/faq-cms-incentive-program.pdf. 
 36. “Basically, 75% of the prescriptions have to be ePrescribed using a certified EHR 
technology to meet the meaningful use guidelines.”  Percent of ePrescribing for Meaningful 
Use, EMR & HIPAA (April 30, 2010), http://www.emrandhipaa.com/emr-and-hipaa/2010/04/ 
30/percent-of-eprescribing-for-meaningful-use; see also D. Scott Jones & Howard B. Kessler, 
Can Electronic Medical Records Really Improve Quality? The Obama Administration Bets Yes, 
J. HEALTH CARE COMPLIANCE, Jan.–Feb. 2010, at 39, 40. 
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prescribing capabilities are explicitly highlighted and emphasized as one 
component of the incentive program.37  E-prescribing of controlled 
substances will likely augment the prescription values used in calculating 
“meaningful use,” but this has yet to be seen at the regulatory level.38  
Although this topic is beyond the scope of the DEA’s regulation, it is 
important to note the DEA regulation will have significant impact on 
practically defining “meaningful use” of e-prescribing for the incentive 
program under MIPPA.39 
The private sector has spurred the growth of e-prescribing as well. 
Several private initiatives, by insurers and other payors, have increased the 
frequency of e-prescribing.40  Most notably the National ePrescribing Patient 
Safety Initiative (“NEPSI”) coalition is dedicated to the increased use of e-
prescribing software.41  NEPSI has offered free software to physicians that 
 
 37. Jones & Kessler, supra note 36, at 40. 
 38. This has yet to be discussed or implemented but the ONC (Office of the National 
Coordinator for Health Information Technology), a branch of HHS, has the duty and plans to 
implement Stage 2 of the incentive program and the new DEA regulation will likely be 
addressed at that time.  See OFFICE OF THE NAT’L COORDINATOR FOR HEALTH INFO. TECH., U.S. 
DEP’T OF HEALTH & HUMAN SERVS., HIT POLICY COMMITTEE: MEANINGFUL USE WORKGROUP 
REQUEST FOR COMMENTS REGARDING MEANINGFUL USE STAGE 2, at 1, 5 (2011), available at 
http://healthit.hhs.gov/portal/server.pt/document/954501/mu_rfc__2011-01-12_final_pdf.  
“[C]MS will have an eye on incorporating the Department of Justice’s policy regarding the 
electronic prescribing of Schedule II drugs, perhaps as soon as the implementation of Stage 
Two eRx meaningful use criteria.”  Mark Faccenda & Lara Parkin, Meaningful Use—What 
Does It Mean to You?, HEALTH LAW., Feb. 2011, at 10, 13.  This author speculates that if the 
physician must e-prescribe a certain percentage of prescriptions each quarter or annually, the 
controlled substances will be included in those calculations once controlled substances are 
able to be e-prescribed.  See id.  Additionally, it could be speculated that controlled 
substances would not be used in the calculation if a given state were not allowing providers to 
e-prescribe controlled substances. 
 39. Electronic Prescriptions for Controlled Substances, DRUG ENFORCEMENT ADMIN. (Mar. 
31,2010), http://www.deadiversion.usdoj.gov/ecomm/e_rx/faq/eapplications.htm [hereinafter 
DEA eRx]. 
 40. A small list of private initiatives include: Massachusetts eRx Collaborative, 
Southeastern Michigan e-Prescribing Initiative, National ePrescribing Patient Safety Initiative, 
BlueCross Blue Shield E-Prescribing Programs, and Individual State Initiatives.  CTR. FOR 
HEALTH TRANSFORMATION, ELECTRONIC PRESCRIBING: BUILDING, DEPLOYING, AND USING E-
PRESCRIBING TO SAVE LIVES AND SAVE MONEY 16-24 (2008), available at http://www.sures 
cripts.com/media/660347/cht_eprescribing_paper_06.10.2008.pdf. 
 41. “This coalition-based program is comprised of healthcare, technology and provider 
companies dedicated to positively impacting the national prescribing process through 
electronic prescribing (ePrescribing) delivery.  NEPSI delivers on this commitment by offering 
free ePrescribing to every physician and medication prescriber in America.”  About Us, NAT’L 
EPRESCRIBING PATIENT SAFETY INITIATIVE (2008), http://www.nationalerx.com/about-us.htm. 
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encounter financial barriers in their practice.42  The private initiatives noted 
are merely a small sample of programs started to encourage the growth of 
e-prescribing.43  Beyond the MMA,44 Physician Incentive Program,45 and 
private or state initiatives,46 the new DEA regulation will have significant 
impact in removing the “controlled substance barrier” or excuse stopping 
prescribers from implementation.47  The DEA rule closes a major loophole 
in e-prescribing language by authorizing e-prescribing for all medications. 
There are barriers to implementation of e-prescribing for providers, 
pharmacies, and patients.  There is a substantial financial cost to providers, 
pharmacies, and insurers to set-up the necessary hardware and software, 
not to mention the requisite training for staff, to ensure a successful e-
prescribing program is in place.48  In particular, independent physician 
offices and small health systems may not immediately realize the return on 
investment (“ROI”) from e-prescribing.49  With high initial set-up costs and a 
low pay-out, for efficiency and streamlined communication, cash-strapped 
physician offices have had little incentive to implement an e-prescribing 
system.50  However, large health systems that have implemented an all 
encompassing EHR system have found it much easier to integrate an e-
prescribing component.51 
 
 42. “NEPSI aims to eliminate the burdens and barriers to ePrescribing adoption that can 
be experienced by providers.”  Prescribers, NAT’L EPRESCRIBING PATIENT SAFETY INITIATIVE 
(2008), http://www.nationalerx.com/prescribers.htm.  Allscripts, a leading e-prescribing 
intermediary that hosts the e-prescribing service, offers software, internet hosting, training, and 
support to all eligible prescribers.  Id.  Ultimately the NEPSI project helps implement, promote, 
and utilize e-prescribing practices for poor, small, and sometimes rural physician offices.  See 
id. 
 43. CTR. FOR HEALTH TRANSFORMATION, supra note 40, at 16. 
 44. See Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 
Pub. L. No. 108-173, 117 Stat. 2066 (codified as amended in scattered sections of 42 
U.S.C.). 
 45. See Medicare Improvements for Patients and Providers Act (MIPPA) of 2008, Pub. L. 
No. 110-275, § 132, 122 Stat. 2494, 2527 (to be codified at 42 U.S.C. 1395w-4); eRx 
Incentives, supra note 32. 
 46. CTR. FOR HEALTH TRANSFORMATION, supra note 40, at 16-24. 
 47. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236 
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311). 
 48. EHEALTH INITIATIVE, supra note 10, at 4-5; Steinbrook, supra note 28, at 115; CAL. 
HEALTHCARE FOUND., supra note 11, at 37. 
 49. EHEALTH INITIATIVE, supra note 10, at 4, 6.  Stand-alone e-prescribing systems cost 
approximately $3,000 per physician; fully integrated systems can cost $50,000 per physician. 
NAT’L GOVERNORS ASS’N, supra note 10, at 2; see also Sullivan, supra note 6, at 19. 
 50. EHEALTH INITIATIVE, supra note 10, at 4. 
 51. See Ashish K. Jha et al., A Progress Report On Electronic Health Records in U.S. 
Hospitals, 29 HEALTH AFF. 1951, 1956 (2010); CAL. HEALTHCARE FOUND., supra note 11, at 
38; NAT’L GOVERNORS ASS’N, supra note 10, at 2. 
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There will always be inherent flaws in any e-prescribing system such as 
typos, computer crashes, entry mistakes, unauthorized record retrieval, and 
other errors.52  The data retrieved from a working e-prescribing system is 
only as good as the data that is originally entered.53  Another obstacle that 
has providers and health systems dragging their feet toward e-prescribing 
adoption is the inherent distrust of computer software.54  Computer software 
cannot take into account every patient’s condition and prognosis; what may 
be a dangerous contraindication for one patient may be a life-saving 
therapy for another.55  The fail-safe warnings and alerts can seem 
cumbersome and dangerous in certain areas of medical practice.56  It is 
also important to note a cultural barrier associated with e-prescribing, for 
many physicians and pharmacists the way prescriptions are delivered has 
not changed since the advent of facsimile.57  This new technology is 
interfering with the usual workflow of health care providers.58 
Until recently controlled substances, 10% to 11% of all prescriptions, 
were not eligible for e-prescribing and this may have been a significant 
barrier for practices that focused on prescribing narcotics (i.e. pain clinics, 
headache clinics, and surgical care centers that discharged patients with 
pain medication).59  A final barrier that should be noted one states’ varying 
 
 52. Ross Koppel et al., Role of Computerized Physician Order Entry Systems in Facilitating 
Medication Errors, 293 JAMA 1197, 1198-1200 (2005). 
 53. See id. at 1200-01. 
 54. Scot Silverstein, Barriers to Computerized Prescribing, 280 JAMA 516, 516 (1998).  
“The United States ranks in the bottom half (out of 11 countries) on every metric used to 
measure adoption, including use of electronic medical records (10th), electronic prescribing 
(10th), electronic clinical note entry (10th), electronic ordering of laboratory tests (8th), electronic 
alerts/prompts about potential drug dose/interaction problems (8th) and electronic access to 
patient test results (7th).”  Thomas R. Nathan, Federal Communications Commission, National 
Broadband Plan, Health Care, in 1 BROADBAND & CABLE INDUSTRY LAW 161, 168 (2011). 
 55. See Gordon D. Schiff & David W. Bates, Can Electronic Clinical Documentation Help 
Prevent Diagnostic Errors?, 362 NEW ENG. J. MED. 1066, 1067-68 (2010). 
 56. Tyler Chin, Doctors Pull Plug on Paperless System, AM. MED. NEWS (Feb. 17, 2003), 
http://www.ama-assn.org/amednews/2003/02/17/bil20217.htm; see Thomas Bodenheimer 
& Kevin Grumbach, Electronic Technology: A Spark to Revitalize Primary Care?, 290 JAMA 
259, 261-63 (2003). 
 57. Silverstein, supra note 54, at 516; Chin, supra note 56; see Bodenheimer & 
Grumbach, supra note 56, at 260. 
 58. EHEALTH INITIATIVE, supra note 10, at 5.  But see Gerard P. Filicko, Don’t Drop the 
Baton: e-Prescribing and e-Results Improve Workflow, VITALSTATISTICS, Summer 2006, at 24, 
24, available at http://www.medvirginia.net/includes/20060705_VS_eRx.pdf. 
 59. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236, 16,237 
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311); see 
Douglas Blayney, ePrescribing and Scheduled Narcotics for Pain Control in Cancer Patients, 
ASCO CONNECTION (Jan. 23, 2009, 1:40 AM), http://connection.asco.org/commentary/arti 
cle/id/2648/eprescribing-and-scheduled-narcotics-for-pain-control-in-cancer-patients.aspx. 
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rules and legislative language.60  This legislative or regulatory disarray could 
cause a significant slow-down in the adoption of e-prescribing of controlled 
substances. 
II.  THE NEW DEA RULE SYNOPSIS 
The new DEA rule promulgated in March 2010 has significant impact in 
the area of e-prescribing.  First, the DEA authorized the electronic 
prescribing of controlled substances.61  This essential step closes the disjoint 
between incentivizing the use of e-prescribing but not encompassing 10-
11% of all drugs prescribed nationally, controlled substances.62  By allowing 
controlled substances to be prescribed electronically, physicians and 
pharmacists have one less barrier (or excuse) to hinder their implementation 
of e-prescribing.63 
Second, the regulation enumerates who may e-prescribe controlled 
substances.64  It cannot be an agent (e.g. nurse, receptionist) but must be 
the prescriber.65  Prescribers are eligible if they possess a valid DEA license, 
which may be linked to the e-prescribing information to assist with a 
seamless transition.66  Third, the DEA regulation has implemented 
recordkeeping requirements for e-prescribing of controlled substances.67  
The records must be readily retrievable and must be kept for up to two 
years, which is consistent with the current recordkeeping standards for paper 
prescriptions of controlled substances.68  Additionally, e-prescribing software 
must allow prescribers the ability to review monthly logs of all controlled 
 
 60. EHEALTH INITIATIVE, supra note 10, at 5. 
 61. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,307. 
 62. Id. at 16,237. 
 63. See Kate Ackerman, Long-Awaited DEA Rule on Controlled Substances Could Boost E-
Rx Rates, IHEALTHBEAT (April 8, 2010), http://www.ihealthbeat.org/features/2010/longawait 
ed-dea-rule-on-controlled-substances-could-boost-erx-adoption.aspx#. 
 64. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,311-12. 
 65. Id. at 16,311.  DEA guidance has confirmed and clarified that DEA registrants should 
not delegate prescribing to an agent because a non-prescribing agent is not able to make a 
clinical decision in the place of a prescriber.  See also 21 C.F.R. § 1306 (2010).  Agents’ 
duties are limited to ministerial acts in connection with communicating prescription 
information to a pharmacy. Role of Authorized Agents in Communicating Controlled 
Substance Prescriptions to Pharmacies, 75 Fed. Reg. 61,613, 61,614 (Oct. 6, 2010) (to be 
codified at 21 C.F.R. pt. 1306). 
 66. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,245, 16,307, 
16,312. 
 67. Id. at 16,306-07. 
 68. Id. at 16,307.  This was an issue of contention.  The first rule had a 5-year window 
for record retrieval but after significant “push-back” from medical and pharmacy practitioners, 
the DEA revised this to a 2-year window as is consistent with current paper recordkeeping 
standards.  Id. at 16,261. 
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medications.69  Prescribers are not required to sign off on monthly reports, 
but must have the software capabilities to retrieve the reports.70 
Finally, and most importantly, the DEA established a “two factor 
authentication” requirement.71  The requirement mandates that prescribers 
use two out of three types of authentication to verify their identity before 
transmitting an e-prescription for a controlled substance.72  The three types 
of authentication have been hotly contested, as seen in the comments of the 
DEA Rule.73  The rule requires two of the three methods of authentication: 
(1) a hard token or key type device that the prescriber must have on them;74 
(2) a password or knowledge-based security measure;75 or (3) a biometric 
security measure.76  Succinctly put, something the prescriber knows, has in 
 
 69. Id. at 16,263 
 70. Initially, the rule called for prescribers to review and sign a monthly log and keep the 
log in a separate record for DEA review.  After the initial comment period, this rule was 
reduced to simply printing and retrieving such logs.  Physicians successfully argued that with 
the implementation of e-prescribing and more paperwork this monthly log redundancy would 
severely inhibit workflow.  Id. at 16,262-63. 
 71. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,312.  
Commentators voiced initial concern that a two-factor method would be too burdensome; 
however, the DEA insisted on a two-factor security measure citing specific internal security 
issues.  Id. at 16,249.  “The problem DEA is addressing with the requirement for two-factor 
authentication credentials is not that someone may use their own authentication credential to 
alter or create a prescription, but that a nonregistrant will use a registrant’s authentication 
credential to create and sign a prescription.”  Id. The risk for a single authentication/password 
to be duplicated or given out is too great a risk to the internal security of a physician’s office.  
Id. 
 72. Id. at 16,312. 
 73. Id. at 16,249. 
 74. The hard token itself must be separate from the computer and physically in possession 
of the prescriber.  Id. at 16,312.  During the rules comment period, commenters suggested a 
swipe card, key-like device, or any other physical object, which would identify and give access 
to the physician.  Id. at 16,253.  For example, if a physician had a password and token the 
computer entry would be similar to an ATM interaction.  Id. at 16,243. 
 75. The DEA recognized and addressed password security standards in reference to 
length, complexity, and prescriber’s ability to remember the password.  Electronic Prescriptions 
for Controlled Substances, 75 Fed. Reg. at 16,312 (citing KAREN SCARFONE & MURUGIAH 
SOUPPAYA, NAT’L INST. OF STANDARDS & TECH., NIST SPECIAL PUB. 800-118, GUIDE TO 
ENTERPRISE PASSWORD MANAGEMENT (DRAFT) ES1 (2009), available at http://csrc.nist.gov/publi 
cations/drafts/800-118/draft-sp800-118.pdf).  Software companies are expected to produce 
password authentication measures based on these generally accepted password standards. Id. 
at 16,249. 
 76. The DEA found that 18% of prescribers use (and 36% plan to use) biometric markers 
for log-in to EHR systems which compelled the DEA to include, but not mandate, use of 
biometrics.  Id. at 16,250.  Biometric passcodes could include fingerprint scans, retina scans, 
etc . . . which must operate at a generally acceptable accuracy and “false match rating.”  Id. 
at 16,312. 
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his or her possession, or the prescribers himself or herself.77  In addition to 
these authentication measures, the DEA has recognized that an actual 
electronically scanned signature could accompany the prescriptions.78 
There have been other specific concerns brought to light within the 
comments but many of those addressed were grouped together and 
summarized by the DEA’s response.79  Arguably many of these concerns are 
minor in nature and can be solved through DEA guidance in the future.  It is 
reasonable to assume the DEA cannot solve unascertained problems given 
that e-prescribing technology is constantly evolving. 
III.  THE STATE AND FEDERAL INTERPLAY 
With the implementation of these new rules it could be argued that 
finally, after years, e-prescribing is reaching full integration into the health 
care delivery model.80  Prior to the new rule, prescribers and pharmacies 
were not allowed to write for or dispense prescriptions for controlled 
substances (CI-CV) via electronic means.81  Controlled substance 
prescriptions make up 10 – 11% of all prescribed medications and until now 
were a missing link in the chain of medication delivery.82  Controlled 
substances are habit-forming medications that are rated on their medical 
necessity and potential for abuse.83  From drugs that are labeled CI (e.g. 
 
 77. Id. at 16,312. 
 78. The DEA wants to grant prescribers the flexibility and the authority to customize their 
prescriptions.  Id. at 16,260.  The DEA further notes that the use of a physical signature is 
optional but the “two-factor” authentication is mandatory.  Id.  The reliance on a single 
password system is not secure enough and is often considered the weakest link in technology 
security.  Id. at 240. 
 79. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,244.  The DEA 
gave consideration to over 200 different comments while drafting the interim final rule that is 
now being implemented.  DEA eRx, supra note 39; see also Ken Tubman, ePrescribe 
Controlled Substances in 2010?, E-PRESCRIBING BLOG (Mar. 30, 2010), http://www.epre 
scribing.org. 
 80. Overview: E-Prescribing, CTRS. FOR MEDICARE & MEDICAID SERVS., https://www.cms. 
gov/eprescribing/ (last visited Jan. 2, 2012). 
 81. M. Susan Ridgley & Michael D. Greenberg, Pharmacy, Facsimile, and Cyberspace: 
An Examination of Legal Frameworks for Electronic Prescribing, 13 ALB. L.J. SCI. & TECH. 1, 33 
(2002). 
 82. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,237; Lawrence 
Bell, Health Care Primer: E-Scripts, Physician-Pharmacists Safe Harbors, Additional Physician 
Revenue, J. COMPENSATION & BENEFITS, May/June 2008, at 14, 24 (2008); see also 
Ackerman, supra note 63. 
 83. DRUG ENFORCEMENT ADMIN., U.S. DEP’T OF JUSTICE, PRACTITIONER’S MANUAL: AN 
INFORMATIONAL OUTLINE OF THE CONTROLLED SUBSTANCES ACT 5, 6 (2006) [hereinafter 
PRACTITIONER’S MANUAL], available at http://www.deadiversion.usdoj.gov/pubs/manuals/ 
pract/pract_manual012508.pdf; see generally 21 C.F.R. §§ 1308.11-.15 (2010) 
(categorizing specific substances and chemical compounds). 
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heroin) to drugs labeled CV (e.g. codeine cough syrup) the Secretary of 
Health and Human Services (“HHS”) categorizes and enforces federal 
regulations on all habit-forming medications.84  The authority to do so was 
granted by Congress in the Controlled Substance Act (“CSA”)85 and 
subsequent DEA regulations.86  The DEA however, does not have the 
authority to preempt state laws or mandate states enforce e-prescribing of 
controlled substances at the state level.87  While the constitutionality of the 
DEA regulations is beyond the scope of this article, the interplay between 
state and federal regulations of controlled substances must be addressed to 
truly understand how this regulation may be implemented.88 
Although the CSA grants the federal government authority over all 
controlled substance, from manufacturing to dispensing, HHS and DEA 
work in close collaboration with state regulatory agencies (e.g. state boards 
of medicine, pharmacy, nursing).89  States retain the ability to legislate and 
regulate more stringently beyond the DEA and other federal regulations 
concerning controlled substances.90  Traditionally, the federal role in 
prescription drug management has been three-fold: (1) the DEA has the 
authority to register providers and dispensers of controlled substances; (2) 
the DEA has the ability to classify narcotic medications; and (3) the DEA 
enforces all federal drug policy.91 The DEA registers92 and regulates 
pharmacies.93  Every pharmacy that dispenses controlled substances has a 
 
 84. The Secretary of HHS has the actual authority to schedule all controlled drugs but 
does so at the professional expert opinions of both the FDA and DEA. 21 C.F.R. § 1308.43 
(2010). 
 85. See generally 21 U.S.C. §§ 801-890 (2006). 
 86. See generally 21 C.F.R. §§ 1300-1316 (2010) (granting DEA approval and 
regulatory authority over controlled substance activities). 
 87. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,304. 
 88. Lars Noah, Ambivalent Commitments to Federalism in Controlling the Practice of 
Medicine, 53 U. KAN. L. REV. 149, 177 (2004). 
 89. “The DEA registration grants practitioners federal authority to handle controlled 
substances.  However, the DEA registered practitioner may only engage in those activities that 
are authorized under state law for the jurisdiction in which the practice is located.”  
Practitioner’s Manual, supra note 83, at 7. 
 90. Id. 
 91. See generally id. at 5-13 (describing the DEA’s procedures for registration, 
classification, and reporting). 
 92. The DEA requires each individual prescriber to register if they wish to write 
prescriptions for controlled substances.  Id. at 7.  Individual pharmacists do not need to 
register, but rather the pharmacy entity itself must register with the DEA if they wish to dispense 
controlled drugs.  Id. at 8. 
 93. “[Pharmacist/Pharmacy] must issue an official order form (DEA Form 222) or an 
electronic equivalent to the registrant transferring the drugs.”  DRUG ENFORCEMENT ADMIN., 
U.S. DEP’T OF JUSTICE, PHARMACIST’S MANUAL: AN INFORMATIONAL OUTLINE OF THE CONTROLLED 
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DEA registration number and must execute special “222 Order Forms” to 
procure prescription medication from a drug wholesaler or manufacturer.94 
Coupled with the DEA influence over controlled substances, individual 
states have significant power to influence controlled substance regulations.95  
States may create controlled substance regulations that are more stringent 
than the CSA96 or DEA regulations97 either through classification of 
medications, recordkeeping requirements, or even where controlled 
medication may be stored.98  An example of a state legislating beyond the 
DEA is in Illinois. Illinois classified the drug Talwin® (pentazocine) as a CII 
narcotic99 whereas the DEA classified the drug as a CIV a narcotic.100  States 
always reserve the right to implement stricter regulations than those 
 
SUBSTANCES ACT 10 (2010) [hereinafter PHARMACIST’S MANUAL], available at 
http://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_manual.pdf. 
 94. There are a number of forms that pharmacies must execute to be eligible for the 
purchase, transfer, and dispensing of controlled drugs (e.g. 222 Form, 41 Form, 224 Form, 
etc.).  Id. at 13; DRUG ENFORCEMENT ADMIN., FORM DEA-224 APPLICATION FOR REGISTRATION, 
available at http://depts.washington.edu/uwmedres/professional/faq_files/224_form_09 
05.pdf (last visited Jan. 2, 2012); SAMPLE DEA FORM 222, available at http://www.zoo 
pharm.net/images/pdf/dea222-sample.pdf (last visited Jan 2, 2012). 
 95. For example, West Virginia and Arizona have in place a more stringent controlled 
substance monitoring program in addition to a separate registration of all prescribers.  See W. 
VA. CODE ANN. § 60A-9-3 (LexisNexis 2011); ARIZ. REV. STAT. § 36-2608 (LexisNexis 2011).  
Iowa has had a separate registration process in effect for a number of years.  See IOWA BD. 
OF PHARMACY, NEW IOWA CONTROLLED SUBSTANCES ACT REGISTRATION APPLICATION (2011), 
available at http://www.iowa.gov/ibpe/pdf/csa-new.pdf.  Delaware has set-up a separate 
group, Delaware Office of Controlled Substances, to deal with all controlled substance 
monitoring and prescribing within the state. DEL. CODE ANN. tit. 16, §§ 4701-4796 (2011). 
 96. See 21 U.S.C. §§ 801-890 (2006). 
 97. The examples in note 95 go above and beyond the call of the DEA regulations and 
the normal standards set forth by the federal agency.  See generally 21 C.F.R. §§ 1300-1316 
(2010). 
 98. See 720 ILL. COMP. STAT. 570 / 312(a) (2010).  Wisconsin requires that all CII 
narcotic medication be either stored in a safe or stored in a manner that is not easily 
accessible.  WIS. ADMIN. CODE PHAR. § 6.07 (2010). 
 99. 720 ILL. COMP. STAT. 570 / 312(a) (2010).  The Illinois Department of Financial and 
Professional Regulations, an overarching department including the Illinois Board of Pharmacy, 
has found Talwin® (pentazocine/naloxone) to be a drug of particular abuse in certain regions 
of Illinois and has thus scheduled it separately from the DEA regulations.  May Annexton, 
Pentazocine Reclassified in Illinois, 240 JAMA 2234, 2235 (1978).  The Illinois Board of 
Pharmacy requires special “222-like” order forms be completed and sent to the Board in 
order for any pharmacy to purchase and dispense Talwin®.  Id. 
 100. DRUG ENFORCEMENT ADMIN., U.S. DEP’T OF JUSTICE, CONTROLLED SUBSTANCES—BY 
DEA DRUG NUMBER 10 (2011), available at http://www.deadiversion.usdoj.gov/schedules/or 
angebook/d_cs_drugcode.pdf. 
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established by the DEA.101  Another example of states legislating around the 
CSA is a more stringent record-keeping requirement. Some states 
(Nebraska102 and Oregon103) require that pharmacies maintain controlled 
substance records for several years after dispensing the medication.  The 
DEA regulation only requires records to be maintained for two years.104 
It is possible to have a disconnect between the goals and standards of 
the DEA and the execution, implementation, and enforcement of regulations 
at the state level.  A competing interest might influence how this new DEA 
regulation may be enforced.  Ultimately, the practical implications of e-
prescribing controlled substances rests within the states’ control, and the 
DEA’s regulations are simply a baseline for the states to implement.105 
With this new rule, health care providers will be able to write for and 
dispense all prescriptions electronically, if they so choose.106  Health care 
providers, pharmacies, and government entities are reexamining barriers to 
e-prescribing, as evidenced by the comments to the DEA rule.107  Some of 
these traditional barriers to e-prescribing will still be at issue, such as 
financial barriers,108 cultural barriers,109 training,110 and privacy.111  
However, additional barriers at the state level may be of increasing concern, 
 
 101. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236, 16,304 
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311); 
PRACTITIONER’S MANUAL, supra note 83, at 7. 
 102. Controlled substance records must be retained for five years.  NEB. REV. STAT. § 28-
411 (2008). 
 103. Records of all prescriptions must be kept for three years.  OR. REV. STAT. § 689.508 
(2009). 
 104. PHARMACIST’S MANUAL, supra note 93, at 13.  However, many states only require a 
two-year record keeping standard as well.  See, e.g., 04-02-0010 ARK. CODE R. § 70 
(LexisNexis 2010); MINN. STAT. ANN. § 151.211 (West 2011); IOWA ADMIN. CODE r. 657-21-5 
(2009). 
 105. PRACTITIONER’S MANUAL, supra note 83, at 7. 
 106. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,236. 
 107. Id.; see also Ackerman, supra note 63. 
 108. EHEALTH INITIATIVE, supra note 10, at 4; Ackerman, supra note 63. 
 109. Silverstein, supra note 54, at 516. 
 110. EHEALTH INITIATIVE, supra note 10, at 4. 
 111. Michael D. Greenberg et al., Electronic Prescribing and HIAPA Privacy Regulation, 41 
INQUIRY 461, 466 (2004); Angela Ferneding, Regional Health Information Organizations: 
Lower Health Care Costs, Fewer Iatrogenic Illnesses, and Improved Care—What Are We 
Waiting For?, 22 J. L. & HEALTH 167, 181-82 (2009); Sullivan, supra note 6, at 18. 
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such as regulatory inconsistencies at the state level,112 drug diversion, or 
data security.113 
IV.  FOCUSING IN ON STATE REGULATORY BARRIERS: UNADDRESSED ISSUES 
This may leave the DEA and e-prescribing stakeholders in a precarious 
position.  The DEA has promulgated a rule that took years to come to 
fruition.114  At least two presidential administrations115 and Congressional 
sessions116 have backed e-prescribing; and now the rule is ready to be 
implemented.  States may still legislate around the DEA rule by passing 
more stringent laws and regulations.117  This paper will address the varying 
legislative structure of states’ e-prescribing laws and the motivating factors 
behind their decisions to legislate or to stay silent on this new medication 
delivery process that the federal government has so heavily invested in.118 
States may for many reasons see e-prescribing as a potential risk.  States 
may be resistant to e-prescribing because of privacy issues,119 forgery or 
diversion risks,120 increase in costs to small or rural prescribers,121 or simply 
 
 112. Most states have not addressed e-prescribing and STARK and anti-kickback 
implications.  Ferneding, supra note 111, at 178-180; Sullivan, supra note 6, at 19.  See 
generally Bell, supra note 82, at 22-24. 
 113. Gilman & Cooper, supra note 5, at 282-83; Ferneding, supra note 111, at 183-84; 
Sullivan, supra note 6, at 17-18. 
 114. The first attempt at e-prescribing of controlled substances was on April 1, 2005.  Lisa 
M. Power, DEA Final Rule Sets The Course For E-Prescribing of Narcotics, HEALTH LAW., Aug. 
2005, at 32, 32; Overview: E-Prescribing, supra note 80. 
 115. Jones & Kessler, supra note 36, at 41; Seth H. Lundy et al., Just What the Doctor 
Ordered? CMS and DEA Introduce New Measures to Facilitate E-Prescribing, J. HEALTH & LIFE 
SCI., July 2009, at 79, 85. 
 116. Lundy et al., supra note 115, at 85. 
 117. Precedent of disregard for the DEA’s regulations is prominently illustrated by 
California’s regulation and validation of marijuana prescriptions.  CAL. HEALTH & SAFETY CODE 
§ 11362.5 (West 2011).  Other states have created legislation to legislate around less 
controversial DEA regulations.  See, e.g., NEB. REV. STAT. § 28-411 (2008), 720 ILL. COMP. 
STAT. 570 / 312(a) (Supp. 2009). 
 118. In 2010 alone, CMS budgeted and spent over $24 million dollars for e-prescribing 
and requested $27.7 million in 2011.  CTRS. FOR MEDICARE & MEDICAID SERVS., U.S. DEP’T OF 
HEALTH & HUMAN SERVS., FISCAL YEAR 2011: JUSTIFICATION AND ESTIMATES FOR APPROPRIATIONS 
COMMITTEES 3, 66 (2011), available at http://www.cms.gov/PerformanceBudget/Downloads/ 
CMSFY11CJ.pdf. 
 119. Greenberg et al., supra note 111, at 466; Ferneding, supra note 111, at 183; 
Sullivan, supra note 6, at 18. 
 120. Gilman & Cooper, supra note 5, at 283; Ferneding, supra note 111, at 182-83; 
Sullivan, supra note 6, at 17-18. 
 121. EHEALTH INITIATIVE, supra note 10, at 4; Ackerman, supra note 63. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
228 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 5:213 
lag behind the DEA regulation change,122 an statute and rule language 
disarray.123  To further analyze states responses to the DEA rule this analysis 
must delve into state language and motivations to better understand the 
nature of implementation of e-prescribing. 
California may be the most favorably situated state to implement e-
prescribing of controlled substances.124  California’s statutory and regulatory 
language seems consistent with the DEA regulation and is so flexible that 
there seems to be cohesion between statute,125 regulation,126 and 
enforcement guidelines.127 
With the approval of the CA BoP and the Department of Justice, a 
pharmacy may receive electronic data transmission prescriptions or 
computer entry prescriptions or orders for C II, III, IV, or V drugs if 
authorized by federal law and in accordance with regulations promulgated 
by DEA.  The CA BoP shall maintain a list of all such requests and approvals 
granted.128 
Additionally, the deputy attorney general has pressed for a quick 
adoption to e-prescribing of controlled substances.129  Current statutes allow 
for adoption of e-prescribing of controlled substances as soon as feasibly 
possible.130  The California legislature wisely adopted language that gave 
 
 122. See Narcotic Enforcement, N.Y. DEP’T OF HEALTH, http://www.health.state.ny.us/pro 
fessionals/narcotic/ (last visited Jan. 2, 2012). 
 123. Many states have conflicting legislation and code language See W. VA. CODE ANN. § 
30-5-12c(a), (c) (LexisNexis 2011). 
 124. Jeff Todd, E-prescribing in a Changing Legal Environment, RICH. J.L. & TECH., Spring 
2006, at 1, 11-12. 
 125. “Electronic transmission of prescriptions is generally permitted.”  CAL. BUS. & PROF. 
CODE § 4040 (West 2011).  For over fourteen years, California has included e-prescription as 
a valid mode of prescription transfer in its laws.  Joshua A. Room, Deputy Att’y Gen., Cal. 
Dep’t Justice, Presentation to the California Board of Pharmacy: The Legal Landscape of 
Electronic Prescribing (E-Prescribing) in California (Nov. 20, 2008), available at 
http://www.pharmacy.ca.gov/meetings/agendas/legal_landscape.pdf. 
 126. California regulations requiring the components of a prescription are not technology-
specific and, as such, can be interpreted within e-prescribing mediums.  Room, supra note 
125. 
 127. Upon DEA approval, the Board of Pharmacy in California and the local DOJ liaisons 
have the authority to “green-light” e-prescribing of controlled substances.  Id.; see also CAL. 
HEALTH & SAFETY CODE § 11164.5(a) (West 2011); Stephen Barlas, DEA Opens the Door to e-
Prescribing of Controlled Substances: But Pharmacies Balk at Security Rules, 33 P&T 626, 626 
(2008). 
 128. HEALTH & SAFETY § 11164.5(a). 
 129. The deputy attorney general noted that California is “poised” for DEA approval.  
Room, supra note 125. 
 130. See HEALTH & SAFETY § 11164.5(a). 
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the Board of Pharmacy, Department of Justice, and DEA the final check on 
any e-prescribing of controlled substance policies.131 
California has amended its laws to skirt anti-kickback rules by creating 
“safe harbors” for e-prescribing.132  This potentially will facilitate a greater 
adoption of the practice. States that do not have safe harbors or carve-outs 
to anti-kickback legislation may find that prescribers expose themselves to 
fraud and abuse liability.133  This issue is addressed on a federal level,134 
and certain states may have addressed this after the adoption of e-
prescribing of non-controlled substances,135 however, states that employ 
 
 131. Only with the approval of the Board of Pharmacy and the Department of Justice, and 
only if authorized by federal law and DEA regulations, may a hospital or pharmacy receive e-
prescriptions for any controlled substance.  Id.  Additionally, one of the California Board of 
Pharmacy’s stated objectives in their strategic plan to is analyze and implement the legal 
requirements of e-prescribing of controlled substances at the earliest date.  CAL. STATE BD. 
PHARMACY, STRATEGIC PLAN 2006-2011, at 12 (2009), available at http://www.pharma 
cy.ca.gov/publications/strategicplan_2009.pdf. 
 132. CAL. WELF. & INST. CODE § 14107.2(c)(4) (West 2011); CMS Proposes New 
Exemptions for 2012 E-Prescribing Penalty, CAL. MED. ASS’N. (May 31, 2011), http://www.cm 
anet.org/news/detail?article=cms-adds-new-exemptions-for-2012-e-prescribing. 
 133. See Kathy Poppit et al., New E-Prescribing and EHR Exceptions and Safe Harbors, 
HEALTH LAW. NEWS, Nov. 2006, at 24, 25-26, available at http://www.healthlawyers.org/Mem 
bers/PracticeGroups/LS/Documents/Poppitt.pdf; see also Federal Fraud and Abuse: Anti-
Kickback Statute, TELEHEALTH RESOURCE CENTER, http://www.telehealthresourcecenter.org/tool 
box-module/federal-fraud-and-abuse-anti-kickback-statute (last visited Jan. 2, 2012) 
(explaining that states can have anti-kickback statutes varying from the federal one, but that 
specific exceptions for electronic prescribing can exist).  Many states have anti-kickback 
statutes, including California, Florida, Georgia, Massachusetts, New Jersey, North Carolina, 
and Texas. Anti-Kickback Law and Suspect Financial Agreements: FAQ, AM. C. OF RADIOLOGY 
(Apr. 1999), http://www.acr.org/secondarymainmenucategories/businesspracticeissues/fea 
turedcategories/antikickback/antikickbacklawandsuspectfinancialagreementsfaqdoc3.aspx. 
 134. The e-prescribing STARK law exception was required by the Medicare Prescription 
Drug Improvement and Modernization Act of 2003, and states that the agency's authority to 
issue the electronic medical record exception is justified under the agency’s “legal authority 
under section 1877(b)(4) of the [Social Security Act].”  Medicare Program; Physicians Referrals 
to Health Care Entities With Which They Have Financial Relationships; Exceptions for Certain 
Electronic Prescribing and Electronic Health Records Arrangements, 71 Fed. Reg. 45,140, 
45,140 (Aug. 8, 2006) (to be codified at 42 C.F.R. pt. 411).  This exception was effective in 
October 2006 and expires in 2013.  Ferneding, supra note 111, at 179; see 42 C.F.R. 
§1001.952 (2010).  This 2006 rule by CMS preempts states from disallowing e-prescribing 
for any federally funded plans and carves out e-prescribing from the anti-kickback statute.  Id.  
However, non-federally funded individuals are still regulated by the laws of the state via 
private insurance companies; Medicaid is not mandated by incentive programs to e-prescribe 
yet either.  Id.; see also NAT’L CONFERENCE OF STATE LEGISLATURES, ELECTRONIC PRESCRIBING 4-
5 (2009), available at http://www.ncsl.org/documents/health/eprscrb0209.pdf (noting that 
although Medicaid does not fall under the Medicare e-prescribing program, efforts exist in 
states to establish similar programs). 
 135. EHEALTH INITIATIVE, supra note 10, at 7. 
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anti-kickback legislation may need to accommodate for a new surge in 
adoption of e-prescribing.136 
In 2008, California Governor Arnold Schwarzenegger proposed 
legislation to mandate e-prescribing capabilities for all California 
prescribers and pharmacies.137  Another great driver of California’s 
favorable e-prescribing environment is the California HealthCare 
Foundation (“CHCF”) which has championed the cause through pilot 
projects, market assessments, and facilitation of discussions.138  California’s 
incentive programs are numerous at the public and private level.  Private 
insurance payors are incentivizing e-prescribing beyond the scope of the 
federal initiatives.139  California’s flexible, all-encompassing statute and rule 
language will allow for what appears to be a seamless adoption of the DEA 
regulations.  Some states are not far behind California’s example.  Arizona 
is similarly situated with legislation that reads: 
For electronic transmission of a Schedule II, III, IV, or V controlled substance 
prescription order, the medical practitioner and pharmacy shall ensure that 
the transmission complies with any security or other requirements of federal 
law.140 
This law seems to be in compliance with the new DEA regulation making 
Arizona ready to implement e-prescribing of controlled substances. Utah is 
another forward thinking state with its passage of the Electronic Prescribing 
Act.141  Utah requires, a prescriber to ask the patient if they would like to opt 
into an e-prescribing program.142  The law also requires all pharmacies be 
 
 136. See NATIONAL CONFERENCE OF STATE LEGISLATURES, supra note 134 at 4-5. 
 137. Governor Schwarzenegger’s health plan, under Senate Bill ABX1 1, would have 
mandated all pharmacies, prescribers, and insurance plans be able to e-prescribe by January 
1, 2012. CAL. STATE S., S. HEALTH COMM. ANALYSIS, HEALTH INSURANCE REFORM, ABX1 1, 1st 
Extraordinary Sess., at 40 (2008), available at http://senweb03.senate.ca.gov/committee/stan 
ding/health/ABX1.pdf. 
 138. Fostering Adopting of E-Prescribing in California, CAL. HEALTHCARE FOUND. (Nov. 
2008), http://www.chcf.org/projects/2008/fostering-adoption-of-eprescribing-in-california. 
 139. The state Medicaid program, Medi-Cal, has worked with local providers, pharmacists, 
and private insurance entities to facilitate comprehensive pilot programs to iron out any 
wrinkles to the e-prescribing system.  SUSAN L. LEONG, L.A. CARE HEALTH PLAN, E-PRESCRIBING 
PILOT PROJECT 3 (2008), available at http://www.pharmacy.ca.gov/meetings/agendas/epre 
scribing_pilot_project.pdf; “Medco Health Solutions Inc. and CalPERS (California Public 
Employees Retirement System) have released results of a pilot electronic prescribing initiative 
that showed dispensing rates for generic drugs were 11% higher for physicians who used such 
technology.”  Generics Use Rises with E-Prescribing, CHAIN DRUG REVIEW (Oct. 25, 2010), 
http://findarticles.com/p/articles/mi_hb3007/is_18_32/ai_n56218400/. 
 140. ARIZ. ADMIN. CODE § R4-23-407(F)(2) (2009). 
 141. UTAH CODE ANN. § 58-82-201(1) (2010). 
 142. Id. 
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eligible to receive electronic prescriptions.143  The law preemptively 
accommodates the DEA rule by mandating that a practitioner may not e-
prescribe a drug or device that is prohibited by federal law or federal 
rule.144 
States like Arizona, Utah, and California145 now are only waiting on the 
proper, secure hardware and software for the two-factor authentication 
methods to be implemented at the prescriber level.146  The DEA along with 
several technology stake-holders147 are issuing studies and pilot programs to 
take the DEA regulation and put into practice appropriate, verification 
technology.148  To comply with technology requirements of the DEA 
regulation: 
The application provider must either hire a qualified third party to audit the 
application or have the application reviewed and certified by an approved 
certification body.  The auditor or certification body will issue a report that 
states whether the application complies with DEA’s requirements and 
whether there are any limitations on its use for controlled substance 
prescriptions.149 
 
 143. Id. § 58-82-201(3). 
 144. Id. § 58-82-201(2). 
 145. Other states are included in this list as well.  Alabama has included administrative 
language that states: “Prescriptions for controlled substances, whether scheduled pursuant to 
state or federal law, are not authorized until the DEA has adopted applicable regulations, at 
which time all prescriptions for controlled substances must comply with the provisions of any 
such regulation or any later amendments or changes thereto.”  ALA. ADMIN. CODE  r. 680-X- 
2-.32(1)(d) (2011). 
 146. See DEA eRx, supra note 39. 
 147. Id.; see also Knowledge Base: Physician/Prescribers, SURESCRIPTS (Mar. 31, 2010), 
http://www.surescripts.com/support/knowledge-base/physiciansprescribers.aspx#3189 
(SureScripts does not provide any technology, but rather helps pharmacies ensure their existing 
medical software is properly certified to meet e-prescribing requirements); see also 
ePrescribing of Controlled Substances, ADVANCEDMD, http://www.advancedmd.com/pro 
ducts-solutions/eprescribing/eprescribing-controlled-substances/ (last visited Jan 2, 2012) 
[hereinafter ADVANCEDMD] (offering software for e-prescribing systems that ensure DEA 
compliance). 
 148. Electronic Prescriptions for Controlled Substances, 73 Fed. Reg. 36,722, 36,730 
n.12 (Jun. 27, 2008) (to be codified at 21 C.F.R. pts. 1300, 1304, 1306, 1311).  The DEA 
has sent letters to all eligible stakeholders to permit e-prescribing of controlled substances 
pending verification of secure software and internet hosting.  Letter from Mark W. Caverly, 
Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement 
Administration, to Provider of Electronic Prescription Application(s) or Pharmacy Application(s), 
available at http://www.deadiversion.usdoj.gov/ecomm/e_rx/epcs_app_provider_ltr.pdf.  
Additionally, it is important to point out that e-prescribing for controlled substances is currently 
allowed; however, the verification process for secured computer software is currently being 
developed, ADVANCEDMD, supra note 147. 
 149. See DEA eRx, supra note 39. 
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A third-party audit must be conducted before e-prescribing of controlled 
substances are written by a prescriber or dispensed by a pharmacy.150  
Thankfully for practitioners and pharmacies, the third-party audit applies to 
the provider of the e-prescribing software, usually the intermediaries or 
software architects.151  The audit itself maintains explicit technological 
requirements that are beyond the scope of this article, but needless to say 
the DEA takes the verification process seriously because external and 
internal security of the system is one of the highest priorities of e-
prescribing.152 
Unlike those states with flexible statutory language that seems to 
coincide with the DEA regulation there are states that have confusing or 
conflicting rules.  State legislation is in constant flux.153  States seem to be 
caught in a situation where their statutes conflict with the new DEA 
regulation. In Iowa, the administrative code states: 
A prescriber may initiate and authorize a prescription drug order utilizing a 
computer or other electronic communication or recording device.  The 
prescription drug order shall contain all information required by Iowa Code 
section 155A.27.  The receiving pharmacist shall be responsible for 
verifying the authenticity of an electronically transmitted prescription or of an 
electronic signature as provided by rule 657—8.19(124,126,155A) or 
21.3(124,155A).154 
It goes further by stating and incorporating: 
21.7(1) Controlled Substances.  A prescription for a controlled substance 
prepared pursuant to this rule may be transmitted to a pharmacy via 
facsimile transmission. 
21.7(2) Noncontrolled prescription drugs.  A prescription for a 
noncontrolled prescription drug prepared pursuant to this rule may be 
transmitted to a pharmacy via computer-to-computer transmission as 
provided in rule 21.8.155 
 
 150. Id. 
 151. The burden of proving security will fall to e-prescribing intermediaries such as 
SureScripts, AllScripts, and other software vendors.  Id. 
 152. See Electronic Prescriptions for Controlled Substances—Interim Final Rule with Request 
for Comment Questions and Answers for Pharmacies, DRUG ENFORCEMENT ADMIN. (Mar. 31, 
2010), http://www.deadiversion.usdoj.gov/ecomm/e_rx/faq/pharmacies.htm (“The audits 
must undergo either a WebTrust, SysTrust, or SAS 70 audit conducted by a person qualified to 
conduct such an audit.”  Alternatively an audit may be done by “a Certified Information 
System Auditor who performs compliance audits as a regular ongoing business activity or a 
DEA approved entity.”). 
 153. Todd, supra note 124, at 17. 
 154. IOWA ADMIN. CODE r. 657-21.7 (2009). 
 155. Id. 
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This type of inconsistent language between the statute and the new DEA 
regulation illustrates where the majority of states are situated.  Much like the 
Iowa Administrative Code, most state statutes and rules are less flexible and 
cannot be read to interpret and then implement e-prescribing of controlled 
substances.156  As seen in Rule 21.7(1) controlled substances may be 
prepared via a facsimile but not via electronic transmission.157  This 
inflexible language by the administrative code warrants change by Iowa 
regulators.158  This change will come with little regulatory difficulty, but the 
devil is in the details of the DEA regulation and state rule comparisons.159  If 
a majority of states need to implement new language how will practitioners 
and stakeholders know if language is consistent throughout each state?  
Most attorneys and legislative aficionados can spot the inconsistency in this 
language, but not all prescribers and pharmacists may focus in on 
legislative nuances. 
Many states after adoption of the DEA regulation will need new 
legislation or rulemaking to provide for clear and concise standards for 
prescribers, pharmacists, and regulators.  These inconsistencies are not 
reserved to a select few states but rather are the norm.160  Additionally, a 
goal of these states should be to draft language that can be interpreted 
liberally with flexibility to the ever-changing technology of medication 
delivery. 
 
 156. Id. 
 157. Although CIII-CV prescriptions may be filled and written pursuant to a facsimile 
prescription, CII prescriptions still require a paper prescription with the eligible DEA 
prescriber’s hand written signature.  Id. 657-10.21(1).  CII narcotic prescriptions may also be 
filled via facsimile under certain exceptions.  Narcotics can be filled via facsimile for 
emergency fills, id. 657-10.22(2) (2009), or for hospice or long-term care patients, id. 657-
10.23(2). 
 158. In a recent August 2011 update, the Iowa Board of Pharmacy proposed a change to 
the administrative code, at IOWA ADMIN. CODE r. 657-21.7(1), which would amend the 
regulation to: “A prescription for a controlled substance may be transmitted by a prescriber to 
a pharmacy via electronic transmission pursuant to DEA [Drug Enforcement Administration] 
requirements for electronic prescribing of controlled substances.”  Update on e-Prescribing of 
Controlled Substances, IOWA BOARD OF PHARMACY NEWS (Iowa Bd. of Pharmacy, Des Moines, 
IA), Aug. 2011, at 5, available at http://www.nabp.net/publications/assets/IA082011.pdf.  
Although this amendment to the Iowa regulations is comprehensive it does not expressly 
address the DEA certification process, transmitting procedures by third party stakeholders, or 
storage of electronic CII prescriptions.  In addition, it is unknown at which time, and if, the 
Board will adopt this amended proposal.  However, this is a positive step in the direction of 
the DEA rule and a streamlining of e-prescribing into current prescriber and pharmacy 
workflow. 
 159. See id. 
 160. See, e.g., D.C. CODE § 48-903.08(a) (2011); FLA. STAT. § 893.04 (2010); GA. 
COMP. R. & REGS. § 480-22-.04(1), (7) (2009). 
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West Virginia is another state that has inconsistencies within its own 
governing statutes and regulations: 
“E-prescribing” means the transmission, using electronic media, of 
prescription or prescription-related information between a practitioner, 
pharmacist, pharmacy benefit manager or health plan as defined in 45 
C.F.R. §160.103, either directly or through an electronic data intermediary.  
E-prescribing includes, but is not limited to, two-way transmissions between 
the point of care and the pharmacist.  E-prescribing may also be referenced 
by the terms “electronic prescription” or “electronic order” . . . . 
. . . . A pharmacist may accept a prescription, including that for a controlled 
substance listed in Schedules II through V, that is communicated in written 
form or by E-prescribing.  A pharmacist may accept a prescription, including 
that for a controlled substance listed in Schedules III through V, and, in 
certain situations, that for a controlled substance listed in Schedule II, that is 
communicated orally (including telephone voice communication) or by way 
of electronic transmission other than E-prescribing.161 
Although the West Virginia rule seems to allow for e-prescribing of 
controlled substances in the first sentence it may read to contradict itself in 
the following sentence.162  This rule may be confusing, as e-prescribing for 
controlled substances is currently prohibited in West Virginia pending DEA 
technology certification and West Virginia’s approval.163  Adding to the 
complexity, the West Virginia statute was recently amended to allow for e-
prescribing of controlled substances, in which the West Virginia Board of 
Pharmacy states the statute is in concert with all other state and federal 
authorities.164 
Notwithstanding any other provision of this code to the contrary, E-
prescribing, as defined in subdivision (15), section one-b of this article, is 
hereby permitted and electronic prescriptions shall be treated as valid 
 
 161. W. VA. CODE R. § 15-1-2.1.18 (2009). 
 162. Id. § 15-1-21.1.1. 
 163. “At this time, prescriptions for controlled substances cannot be sent electronically and 
must be written on tamper resistant prescription blanks for Medicaid patients.  Hand-signed 
hard copies of prescriptions for Schedule III through V drugs can be sent using manual fax 
technologies.  Be sure to follow DEA regulations and refrain from sending controlled 
substance prescriptions electronically.”  WVeScript Online Learning: Frequently Asked 
Questions, W. VA. BUREAU FOR MED. SERVICES, http://www.wvescript.com/frequently_asked_ 
questions (last visited Jan. 2, 2012). 
 164. E-Prescribing and Controlled Substances, FAQs from DEA, W. VA. BOARD OF 
PHARMACY NEWS (W. Va. Bd. of Pharmacy, Charleston, W. Va.), Sept. 2010, at 1, available at 
http://www.nabp.net/publications/assets/WV092010.pdf (citing W. VA. CODE § 30-5-12c 
(2009)).  Until recently, West Virginia was not situated to accept e-prescribing for controlled 
substances, but in this newsletter article, the West Virginia Board of Pharmacy has addressed 
the regulatory language and is convinced they are appropriately situated for a transition to e-
prescribing of controlled substances.  Id. 
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prescriptions orders. E-prescribing of controlled substances shall not be 
permitted, except as provided by emergency rules promulgated by the 
board . . . . 
. . . . All electronic prescriptions shall be transmitted in a manner consistent 
with applicable federal law, rules and regulations, including, but not limited 
to, the Health Insurance Portability and Accountability Act of 1996, 29 
U.S.C. § 1181, as amended, the Medicare Prescription Drug, Improvement 
and Modernization Act of 2003, 42 U.S.C. § 1395w, as amended, the 
Controlled Substances Act of 1970, 21 U.S.C. § 801, as amended, the 
Drug Abuse Prevention, Treatment and Rehabilitation Act, 21 U.S.C. § 
1101, as amended, and the Comprehensive Alcohol Abuse and Alcoholism 
Prevention, Treatment and Rehabilitation Act of 1970, 42 U.S.C. § 4541, 
as amended.165 
It seems to the outside observer reading these statutes that West Virginia is 
attempting to allow e-prescribing in section 30-5-12c(c); by allowing the 
state to apply all applicable federal language.166  However, section 30-5-
12c(1) makes it clear that e-prescribing of controlled substances is not 
allowed in West Virginia until there is promulgation of emergency rules.167  
The spirit of these two statutes seems to be in direct contradiction.  The West 
Virginia Board of Pharmacy states their rules and statutes are in compliance 
with the new DEA regulation, which they seem to be.168  However, with the 
implementation of technology standards by the DEA, West Virginia will have 
to promulgate separate emergency rulemaking procedures to exercise e-
prescribing of controlled substances.169  In situations like this, hurried and 
jumbled language has caused practitioners and pharmacists to give pause 
when considering regulatory inconsistencies surrounding e-prescribing of 
controlled substances.170 Specifically, the timing of e-prescribing 
implementation is unsettled because practitioners will have to wait for 
 
 165. W. VA. CODE § 30-5-12c (2009). 
 166. See id. 
 167. See id. § 30-5-12c(a). 
 168. Id. § 30-5-12c(c).  It is also important to note that West Virginia does have several 
laws on the books that take into account privacy, security, and other issues that relate to the 
barriers and fears of e-prescribing.  See W. VA. CODE R. § 15-1-21.1.8.b (2011).  It seems 
the West Virginia Board of Pharmacy and legislature were extremely prospective in their 
flexible language to comply with all of the pertinent integrity, privacy and security measures at 
the state and federal level.  Id. 
 169. See W. VA. CODE § 30-5-12c(a) (2009). 
 170. Confusing laws always seem to limit or at least make practitioners think twice about 
moving to a given state. Chris Dimick, Fear Factor: Ambiguities in State Law Leave Some 
Providers Hesitant to Adopt EHRs, J. AHIMA, Nov.-Dec. 2009, at 50, 50; see also Jonathan 
Gill, Tough Laws, High Insurance Drive Doctors Away from West Virginia, L.A. TIMES, Jan. 7, 
1990, at A10. 
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emergency rules.171  Even when the CII prescription is allowed e-prescribing 
status, West Virginia prescribers and pharmacists receive no benefit from the 
practice because the subsequent regulation requires a paper prescription for 
all CII medications.172 Currently: 
If a CII prescription is given over the phone or via e-prescribing in an 
emergency situation which is allowed, “the orally communicated prescription 
is immediately reduced to writing by the pharmacist, or, if necessary, the 
prescription communicated by way of electronic transmission is immediately 
reduced to a hard copy.”173 
The contradictions within West Virginia’s statutes and rules seem to 
mean that a prescriber can send a CII prescription via e-prescribing, but the 
electronic prescription must be reduced to writing.  This negates many of the 
potential workflow efficiencies, paper-less benefits, and potential security 
measures offered by e-prescribing.174 
The West Virginia legislative and regulatory confusion brings to light an 
obvious but overlooked sentiment by states: the need to protect from 
prescription drug diversion.175  The DEA addressed this in the background of 
the rule and within their response to rule commentators.176  The DEA 
reasoned e-prescribing would likely cut down on diversion by patients and 
 
 171. See W. VA. CODE § 30-5-12c(a). 
 172. W. VA. CODE R. § 15-1-21.1.6. 
 173. Id. § 15-1-21.1.6.b. 
 174. EHEALTH INITIATIVE, supra note 10, at 2-3; Jason Harris, Going Paperless: EHRs Offer 
Challenges, Benefits, HEMONCTODAY (Aug. 10, 2010), http://www.hemonctoday.com/arti 
cle.aspx?rid=67420.  Ultimately the paperless system will enhance cohesive health delivery, 
create a “greener” health care environment, and increase portability of medical records.  See 
Mark Singh, Benefits of Paperless Record Systems in Hospitals, CLINICORE HEALTH SOLUTIONS 
(Apr. 8, 2010, 6:28 PM), http://clinicore.blogspot.com/2010/04/benefits-of-paperless-
record-systems-in.html. 
 175. Prescription drug diversion is the deflection of prescription drugs from medical 
sources into the illegal market.  PILAR KRAMAN, COUNCIL OF STATE GOV’TS, DRUG ABUSE IN 
AMERICA—PRESCRIPTION DRUG DIVERSION 4 (2004) available at http://www.csg.org/knowledge 
center/docs/TA0404DrugDiversion.pdf.  West Virginia’s laws have been established to reduce 
oral and electronic prescriptions to writing and to confirm those prescriptions with a hard-copy 
from the prescriber to prevent diversion. W. VA. CODE  R. § 15-1-21.1.2 (2011).  The 
American Pharmacists Association (APhA) has expressed the sentiment that there is an 
increased security benefit of e-prescribing to reduce forgeries of prescriptions for controlled 
substance because e-prescribing patients will not have an opportunity to manipulate a paper 
prescription.  Electronic Prescribing of Controlled Substances: Addressing Health Care Law and 
Enforcement Policies: Hearing Before the S. Comm. on the Judiciary, 110th Cong. 2 (2007) 
[hereinafter APhA’s Senate Statement] (statement of  The American Pharmacists Association 
(APhA)). 
 176. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236, 
16,244-45 (proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 
1311). 
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those outside of the health delivery model.177  By not allowing patients to 
have physical contact with the prescription, when taking it from the 
prescriber to the pharmacy, there is less chance for the document to be 
tampered,178 altered or copied for the purpose of abuse.179  However, the 
risk for internal diversion and diversion through technological means is still 
of great concern.180  There is an increased risk of computer hacking or 
manipulation of data through the technology intermediaries that manage 
the e-prescribing software.181 
The two-factor authentication is the DEA’s answer to internal diversion 
issues.  Although this will deter agents in a prescriber’s office or hospital 
from forging controlled substance prescriptions, states and experts alike are 
skeptical.182  Many times computer consoles stay logged-in allowing a 
prescriber easy access, but this opens up an opportunity for potential 
abuse.183  There may also be opportunities for an office employee to 
observe a physician entering a password to use later for diversion purposes, 
a two-factor authentication should limit this problem.184  Additionally, these 
same security pundits find cause for concern about the security of the 
network itself, through hacking.185  Could an enterprising computer expert 
or hacker gain access to an e-prescribing system and then write 
prescriptions that look legitimate?  The answer may be yes.186  There are 
 
 177. Id.; APhA’s Senate Statement, supra note 175, at 2; Barlas, supra note 127, at 626.  
Diversion of controlled substances is “a relatively simple task in the current paper-based 
environment.”  Kathryn Foxhall, HHS, DEA Still at Odds Over E-Prescribing, DRUG TOPICS 
(Aug. 21 2006), http://drugtopics.modernmedicine.com/drugtopics/article/articleDetail.jsp?id 
=365721. 
 178. See Electronic Prescribing of Controlled Substances: Addressing Health Care and Law 
Enforcement Priorities: Hearing Before the S. Comm. on the Judiciary, 110th Cong. (2007) 
(Statement of Joesph T. Rannazzisi, Deputy Assistant Director, Office of Diversion Control, 
Drug Enforcement Administration), available at http://www.justice.gov/dea/pubs/cngrtest/ct 
120407.html. 
 179. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,244. 
 180. Id. at 16,244-45. 
 181. See id. at 16,243; AM. COLL. OF PHYSICIANS, ELECTRONIC PRESCRIBING OF CONTROLLED 
SUBSTANCES—A NEW OPTION 1, http://www.acponline.org/running_practice/technology/epre 
scribing/dea.pdf. 
 182. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,249-250. 
 183. Id. at 16,240. 
 184. Id. at 16,249. 
 185. Id. at 16,242. 
 186. See, e.g., Press Release, Drug Enforcement Administration, Statement for the 
International Day Against Drug Abuse and Illicit Trafficking (June 27, 2008), http://www.jus 
tice.gov/dea/pubs/pressrel/pr062708.html (“DEA Deputy Assistant Administrator for the 
Office of Diversion Control, Joseph Rannazzisi, said ‘Our goal is to put in place an electronic 
prescribing system that is efficient, medically beneficial to patients and prescribers, and 
provides security from hackers and others who might seek to engage in fraudulent prescribing 
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several e-prescribing technology intermediaries that facilitate the 
transmission from the prescriber to the pharmacy.187 The DEA has 
promulgated language that denotes any change to the content of a 
prescription during transmission, including truncation or removal of data, 
will render the electronic prescription invalid.188  As noted above, the DEA is 
working on appropriate technological standards for e-prescribing and soon 
a timeline and implementation of the technology will be outfitted for market 
use.189  However, until that time states may see fit to prepare themselves for 
the new technology through changes in their own statutes and regulations. 
The DEA notes the two-factor authentication and additional computer 
security measures will deter hacking.190  Also, prescribers are required to 
print and observe monthly logs of their controlled substance prescriptions, 
which encourage oversight and security.191  Computer software developers 
have initiated a “hard-stop” in the e-prescribing software that would 
automatically log-out a prescriber after a controlled substance prescription 
is authorized.192  Additionally, the two-factor authentication is needed for 
every controlled substance prescription.193  In actuality, internal diversion 
can occur with or without e-prescribing software and it is up to prescribers, 
insurance companies, and pharmacists to police the transmission of those 
prescriptions.194  It can be argued that a stolen prescription pad from a 
doctor’s office is just as dangerous as a breached e-prescribing system.195 
Finally there is a third subset of states that have not adopted e-
prescribing of controlled substances language.  The Nebraska Board of 
Pharmacy has determined that until the DEA certifies the systems used by 
 
activities.”); see also Jill Wechsler, Health IT Gains Momentum, MANAGED HEALTHCARE 
EXECUTIVE (Jan. 1, 2008), http://managedhealthcareexecutive.modernmedicine.com/mhe/ 
News+Analysis/Health-IT-Gains-Momentum/ArticleStandard/Article/detail/482403.  But see 
CTR. FOR HEALTH TRANSFORMATION, supra note 40, at 12. 
 187. DEA eRx, supra note 39; MD. HEALTH CARE COMM’N, E-PRESCRIBING: AN INFORMATION 
BRIEF 2-3 (2008), available at http://mhcc.maryland.gov/electronichealth/eprescribing/ 
PharmacyBoardReport062408v2.pdf.  It is important to note that both SureScripts and RxHub 
have never reported an incident of hacking or breach in their e-prescribing network.  CTR. FOR 
HEALTH TRANSFORMATION, supra note 40, at 12. 
 188. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,288. 
 189. See supra text accompanying notes 200-06. 
 190. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,242. 
 191. Id. at 16,262. 
 192. Ann Carrns, Special Health IT Report: Electronic Prescribing Increasing Despite 
Glitches, KAISER HEALTH NEWS (June 29, 2009), http://www.kaiserhealthnews.org/Stories/ 
2009/June/29/eprescribe.aspx. 
 193. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,249. 
 194. Id. at 16,261. 
 195. ELECTRONIC PRESCRIBING INITIATIVE, EHEALTH INITIATIVE, ELECTRONIC PRESCRIBING: 
TOWARD MAXIMUM VALUE AND RAPID ADOPTION 73 (2004). 
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prescribers and pharmacies.196  Nebraska will follow current law, not 
change laws on the books and not allow e-prescribing for controlled 
substances.197  The Nebraska statute currently reads: 
[A] controlled substance listed in Schedule II of section 28-405 shall not be 
dispensed without the written prescription bearing the signature of a 
practitioner authorized to prescribe . . . . 
. . . . Except as otherwise provided in this subsection or when administered 
directly by a practitioner to an ultimate user, a controlled substance listed in 
Schedule III, IV, or V of section 28-405 shall not be dispensed without a 
written or oral medical order.198 
Nebraska’s Board of Pharmacy’s software concerns illustrate certain 
privacy issues.199  Additionally, the Nebraska Board of Pharmacy has 
expressed the use of intermediaries is not ideal, and intermediary services 
(also known as a “switch”) burden providers and pharmacists with extra 
costs and security issues.200 
Privacy concerns fall primarily under HIPAA201 through standards 
imposed on the prescriber, pharmacy, and other business entities involved in 
 
 196. The Board requested that staff gather more information from the DEA before changes 
to Nebraska statutes and regulations are pursued.  The Board mentioned having discussions 
with the Department regarding changes that may need to be made to the Uniform Controlled 
Substances Act to allow electronic prescribing in Nebraska. NEB. BD. PHARMACY, MEETING 
MINUTES MAY 10, 2010, at 2 (2010), available at http://dhhs.ne.gov/publichealth/Docu 
ments/051010pharmminutes.pdf. 
 197. Id.; see also NEB. BD. PHARMACY, MEETING MINUTES JULY 12, 2010, at 4 (2010), 
available at http://dhhs.ne.gov/publichealth/Documents/071210pharmminutes.pdf.  It is 
important to note that Nebraska pharmacy leaders are not against e-prescribing of controlled 
substances, the Board of Pharmacy is simply skeptical about the certification process and 
functionality of the security features of the e-prescribing systems.  See EHEALTH COUNCIL, NEB. 
INFO. TECH. COMM’N, E-PRESCRIBING WORK GROUP REPORT AND RECOMMENDATIONS 5-6 
(2009), available at http://www.nitc.nebraska.gov/eHc/plan/reports/EprescribingRecommend 
ations.pdf. 
 198. NEB. REV. STAT. § 28-414(2)(a) (2009). 
 199. See Gilman & Cooper, supra note 5, at 283-84; Sarah Rubenstein, Privacy 
Advocates Sound Alarm About Electronic Prescribing WALL ST. J. HEALTH BLOG (July 29, 2008, 
9:02 AM), http://blogs.wsj.com/health/2008/07/29/privacy-advocates-sound-alarm-about-
electronic-prescribing/; see generally EPRESCRIBING DATA USE TASK GRP., EPRESCRIBING DATA 
USE PROBLEM STATEMENT 4-5 (2009) (discussing various issues surrounding privacy and e-
prescribing). 
 200. EHEALTH COUNCIL, supra note 197, at 4. 
 201. See Health Insurance Portability and Accountability Act (HIPAA) of 1996 Pub. L. 104-
191, § 264, 110 Stat. 2033, 2033-34 (codified as amended at 42 U.S.C. § 1320d-2).  
“HIPAA privacy and security standards still exert influence over several aspects of the 
prescribing process, including storage of and access to related records, as well as the 
communication of records between providers.”  Greenberg et al., supra note 111, at 463.  
“The kind of system integration and data sharing that offers greatest promise for improving 
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electronic health care information.202  Providers and pharmacies have 
adapted to HIPAA standards well but at a significant cost,203 which may lead 
e-prescribing users with an impression that they will be able to adapt quickly 
to any privacy concerns.  However, state privacy laws may impede the 
adoption of the e-prescribing process too.204  E-prescribing and EHR 
systems will ideally allow the free flow of patient data to all parties that 
require the electronic medical information.205  With data becoming more 
accessible the danger is that more privacy violations under HIPAA or state 
privacy law may appear.206 
It seems these concerns may be over-emphasized. With the 
computerization of patient health information (“PHI”) health care entities 
have been able to adequately adapt and change their operations to meet 
both state and federal laws.207  But if necessary, could EHR and e-
 
clinical prescribing practice is also the most challenging aspect of e-Rx under HIPAA and the 
privacy regulations.”  Id. at 465. 
 202. Greenberg et al., supra note 111, at 465. 
 203. Id. at 463. 
 204. “The ultimate goal [is]…to obtain appropriate privacy protections while facilitating the 
development of fully functional, network-based e-Rx systems.  Achieving this goal also could 
involve some marginal tailoring of federal pre-emption of state privacy laws.”  Id. at 467.  
States may have a multitude of different privacy regulations concerning the medical 
community; Iowa for example released a report discussing HIPAA preemption and Iowa 
Privacy laws.  See IOWA HIPPA SNIP, IOWA HIPAA PREEMPTION ANALYSIS: A REPORT ON THE 
RELATIONSHIP BETWEEN HIPAA’S PRIVACY RULE AND IOWA STATUTORY LAW vi (2003), available at 
http://www.iowamedical.org/documents/legal/IowaHIPAAPreemptionAnalysis.pdf.  The HIPAA 
preemption and individual state laws are beyond the scope of this article but it will be 
important for states to address privacy laws as a possible barrier to e-prescribing adoption.  
Greenberg et al., supra note 111, at 465-66. 
 205. “An interoperable system of HIE [health information exchange]—that is, one in which 
various parties can share and exchange data among them—will have difficulty 
accommodating the current range of variation in policy requirements.”  Linda Dimitropoulos & 
Stephanie Rizk, A State-Based Approach to Privacy and Security for Interoperable Health 
Information Exchange, 28 HEALTH AFF. 428, 428-29 (2009). 
 206. An excellent resource to delve into the privacy concerns of EHR and e-prescribing is 
RTI International and their work with National Health Information Security and Privacy 
Collaboration (HISPC).  See Press Release, RTI Int’l, RTI International to Support National 
Health Information Security and Privacy Collaboration (Oct. 12, 2005), http://www.rti.org/ 
page.cfm?objectid=0AD0F1AC-B38F-4286-92481FDE5E224511. RTI International has 
contracted with 34 states to investigate and consolidate privacy laws in states that serve as 
barriers to EHR, Health Information Exchange (HIE), and e-prescribing adoption. LINDA L. 
DIMITROPOULOS, PRIVACY AND SECURITY SOLUTIONS FOR INTEROPERABLE HEALTH INFORMATION 
EXCHANGE—IMPACT ANALYSIS 3-2 (2007), available at http://www.rti.org/pubs/phase2_impact 
analy.pdf; see also Greenberg et al., supra note 111, at 462. 
 207. Greenberg et al., supra note 111, at 462.  Surescript’s statistics note an 181% 
increase in e-prescribing and over 25% of all office based physicians are e-prescribing.  
SURESCRIPTS, supra note 27, at 8, 10. 
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prescribing laws provide a more comprehensive, uniform approach to 
assessing privacy issues?  Too heavy a burden is being placed on national 
health care entities to adhere to a multitude of different state regulations.  
With the exchange of information becoming a national endeavor208 and 
health care entities stretching through all fifty states,209 there must be a 
growing trend for states to consolidate uniform standards for e-prescribing 
and privacy.  New, flexible regulations or statutes must be entertained if not 
adopted. 
The inconsistent regulatory scheme nationwide remains a significant 
barrier to e-prescribing for controlled substance adoption.  As mentioned 
above, technology pilot studies and tests are ongoing and will soon be 
mimicked to allow for a full functioning, secure e-prescribing system.210  
One of the few remaining barriers to e-prescribing is the passive resistance 
of state statutes and regulations.  The inconsistent language provided by the 
majority of the states leaves practitioners, pharmacists, and technology 
intermediaries waiting for state legislative action.  There needs to be a 
conscious and focused effort to implement regulatory amendments to 
accelerate this slow adopting but extremely beneficial health delivery tool.  
With only the technological barriers of DEA certification remaining, state 
regulatory language is one of the final barriers e-prescribing advocates must 
tear down. 
V.  IS MODEL LANGUAGE A SOLUTION? 
Adoption rates of e-prescribing are growing211 but considering the 
federal, state, and private initiatives212 already in place, it is argued that the 
adoption rates of e-prescribing remain sluggish.213  Model language could 
 
 208. See Gilman & Cooper, supra note 5, at 287; SURESCRIPTS, supra note 27, at 11. 
 209. See NAT’L GOVERNORS ASS’N, supra note 10, at 5; Press Release, Walgreens, 
Electronic Prescriptions Soar at Walgreens (Apr. 13, 2009), http://news.walgreens.com/arti 
cle_print.cfm?article_id=5176; Press Release, CVS Caremark, CVS Caremark Announces e-
Prescribing Agreement with Allscripts (Jan. 7, 2010), http://investor.cvs.com/phoenix.zhtml?c 
=99533&p=irol-newsArticle&ID=1372549&highlight=. 
 210. DEA eRx, supra note 39; see also AGENCY FOR HEALTHCARE RESEARCH & QUALITY, 
AHRQ PUBL’N NO. 07-0047-EF, FINDINGS FROM THE EVALUATION OF E-PRESCRIBING PILOT SITES 
v (2007), http://healthit.ahrq.gov/portal/server.pt/gateway/PTARGS_0_8969_227460_0_0_ 
18/Findings%20From%20The%20Evaluation%20of%20E-Prescribing%20Pilot%20Sites.pdf. 
 211. See SURESCRIPTS, supra note 27, at 10-11. 
 212. See, e.g., eRx Incentives, supra note 32; CTR. FOR HEALTH TRANSFORMATION, supra 
note 40, at 16-24; CMS ePrescribing Incentive Program, AM. MED. ASS’N, http://www.ama-
assn.org/ama/pub/physician-resources/health-information-technology/incentive-
programs/cms-eprescribing-incentive-program.page. 
 213. JOY M. GROSSMAN, CTR. FOR STUDYING HEALTH SYS. CHANGE, ISSUE BRIEF NO. 133, 
EVEN WHEN PHYSICIANS ADOPT E-PRESCRIBING, USE OF ADVANCED FEATURES LAGS 1 (2010), 
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be the key to clarifying and quashing many of the barriers e-prescribing 
needs to overcome.214  Significant merit must be given to the DEA rule and 
other e-prescribing initiatives that have spent years on analysis and 
implementation of e-prescribing standards.  But DEA rules may not address 
many of the state regulatory concerns that plague e-prescribing 
implementation.215 
Historically, model language has been created and used by state 
legislatures and agencies to foster change in the regulatory scheme.216  
Model language has been a successful tool throughout the legal community 
for many years,217 for example model language has been drafted for use in 
the health law sector,218 electronic transactions,219 and business code in 
state law.220  E-prescribing model language may allow for a uniform 
transition from old state rules to newer and more current forms of rules.  It 
could provide uniformity to all of the stakeholders of e-prescribing from the 
practitioners, to regulators and third-parties. 
 
available at http://www.hschange.com/CONTENT/1133/1133.pdf; see also Nathan, supra 
note 54 at 203. 
 214. “The work of the ULC simplifies the legal life of businesses and individuals by 
providing rules and procedures that are consistent from state to state—a consideration that 
has become more critical as new technology wears away geographical borders and matters of 
law implicate more than one state.”  Frequently Asked Questions, NAT’L CONF. OF 
COMMISSIONERS ON UNIFORM STATE LAW, http://www.nccusl.org/Narrative.aspx?title=Frequent 
ly%20Asked%20Questions (last visited Jan. 3, 2012) [hereinafter NCCUSL]. 
 215. The DEA rule seems to be silent on state privacy laws, state anti-kickback legislation, 
and separate state licensure of prescribers and pharmacies.  See Electronic Prescriptions for 
Controlled Substances, 75 Fed. Reg. 16,236 (proposed Mar. 31, 2010) (to be codified 21 
C.F.R. at pts. 1300, 1304, 1306, 1311). 
 216. See NCCUSL, supra note 214 (stating “[s]ince the ULC first convened in 1892, it has 
produced more than 250 uniform acts focusing on such areas as commercial law, family or 
domestic relations law, estates, probate and trusts, real estate, implementation of full faith and 
credit, interstate enforcement of judgments, and alternate dispute resolution”). 
 217. See id.; see also ALI Overview, AM. L. INST., http://www.ali.org/index.cfm?fuseaction 
=about.overview (last visited Jan 3, 2012); CORNELL UNIV. L. SCHOOL, Uniform Commercial 
Code Locator: Uniform Law, LEGAL INFO. INSTITUTE, http://www.law.cornell.edu/uniform/ 
uniform.html (last visited Jan. 3, 2012).  One author even goes so far as to entertain 
uniformity of the prescriber’s licensing process. Daniel J. Gilman, Physician Licensure and 
Telemedicine: Some Competitive Issues Raised by the Prospective of Practicing Globally While 
Regulating Locally, 14 J. HEALTH CARE L. & POL’Y 87, 114 (2011). 
 218. See, e.g., UNIF. HEALTH-CARE INFO. ACT § 1-102 (1986), available at http://www.law. 
upenn.edu/bll/archives/ulc/fnact99/1980s/uhcia85.pdf (providing an example of model 
language in the health law sector). 
 219. See, e.g., UNIF. ELEC. TRANSACTIONS ACT § 2 (1999), available at http://www.law.u 
penn.edu/bll/archives/ulc/fnact99/1990s/ueta99.pdf (providing an example of model 
language in electronic transactions). 
 220. See NAT’L CONF. OF COMM’RS ON UNIF. STATE LAW, UNIFORM COMMERCIAL CODE, 
http://www.nccusl.org/Update/ActSearchResults.aspx (last visited February 1, 2011). 
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Model language can also be a source of expertise;221 not all states have 
the time and money to spend on legislative drafting and model language 
can bring in nationally renowned experts to help implement language.222  
Not to mention draft a flexible, forward-thinking uniform rule that would 
accommodate changes in the legal and health delivery environments.223  
Model language takes the burden of drafting off of the states while allowing 
them to implement either the whole or parts of a specific plan.224 
On the other hand, one risk of model language use is that certain sub-
sections of a state’s population would not be accommodated.225  Model 
language “brushes with broad strokes” and as such may not be specific 
enough for states with outlying population groups.226  Additionally, by virtue 
of the drafting process interest groups will undoubtedly have input drafting 
rules or statutes.227  This may create biases.228  Finally, model language may 
take too long or be too involved.  If the language is too cumbersome states 
may choose not to adopt because they fear increased bureaucracy, 
enforcement issues, or incidental cost.229 
As illustrated above, states’ e-prescribing concerns include diversion and 
privacy issues specifically in the realm of computer security and security at 
the point of the prescriber.  State boards of pharmacy or medicine may fear 
they will be inundated with increases in diversion at the physician’s office 
and the burden to investigate and protect against computer hacking—both 
areas that have been traditionally beyond the scope of their regulating 
expertise.  Additionally, states may worry about anti-kickback legislation or 
implications within their own fraud and abuse regulations.  State language 
 
 221. Bruce H. Kobayashi & Larry E. Ribstein, The Non-Uniformity of Uniform Laws, 35 J. 
CORP. L. 327, 328, 343 (2009) [hereinafter Non-Uniformity]. 
 222. See Lawrence J. Bugge, Commercial Law, Federalism, and the Future, 17 DEL. J. 
CORP. L. 11, 19 (1992); Larry E. Ribstein & Bruce H. Kobayashi, An Economic Analysis of 
Uniform State Laws, 25 J. LEGAL STUD. 131, 140 (1996) [hereinafter Economic Analysis]. 
 223. Bugge, supra note 222, at 18-19. 
 224. Non-Uniformity, supra note 222 at 330; Economic Analysis, supra note 222 at 140. 
 225. Economic Analysis, supra note 222, at 142. 
 226. Id. 
 227. “Interest groups can influence uniform law drafters even if these drafters are 
appointed on a nonpolitical basis rather than elected . . . . [Uniform law makers] invite[] 
‘advisers’ representing the groups to attend and participate in drafting and annual meetings.  
Advisers can most influence those commissioners who lack independent knowledge that would 
enable them to take positions that are not advocated at the meetings.”  Id.  Although it would 
seem special interest groups are a “necessary evil” to get buy-in and appropriate expertise 
involved in the drafting process.  See Kathleen Patchel, Interest Group Politics, Federalism and 
the Uniform Laws Process: Some Lessons From the Uniform Commercial Code, 78 MINN. L. 
REV. 83, 100 (1993). 
 228. Economic Analysis, supra note 222, at 143. 
 229. See generally Economic Analysis, supra note 222, at 135-37. 
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should be consistent.  Rules and statutes need to align and guidance by 
boards of pharmacy, medicine and nursing need to be clear. 
Model language has the ability to address specific concerns and resolve 
state privacy barriers, security issues, and inconsistent language.  Sections of 
model language should explicitly address each of these issues while taking 
into account that some states may not adopt a given section.  If this occurs, 
model language would not only have to stand as a cohesive work but each 
section should be well-drafted to stand on its own.  An organization of 
model language may look like this (including but not limited to the following 
sections): 
1)  Model Act for E-prescribing 
  a) §1 Definitions 
   i) Electronic Prescribing 
   ii) Electronic Transmission 
   iii) Prescription 
   iv) Valid Signature 
   v) Valid, eligible Prescriber 
   vi) Eligible Pharmacy (Resident or Non-Resident) 
   vii) Eligible Third Party Intermediaries 
  b) §2 Requirements of an Electronic Prescription (e-prescription) 
   i) Eligible Prescribers and Agents of Prescribers 
    (1) DEA Licensure/Approval 
    (2) State Controlled Substance Licensure 
   ii) Eligible Pharmacies 
    (1) DEA Licensure 
    (2) State Licensure 
   iii) Eligible Software and Systems Management Stakeholders 
    (1) DEA and/or State approval 
    (2) Third party certification 
    (3) Certified Biometrics, Hard Token, Password Specifics 
   iv) Scope of Medication that may be prescribed 
    (1) CII-CV 
    (2) Address CI Research Issues 
    (3) May have the option to limit or line item certain medications 
   v) Information Required (Prescription and Label information) 
    (1) Patient Identifiers 
    (2) Drug Identifiers 
    (3) Prescriber Information 
    (4) Prescription Information (Refills, Quantity, Drug, Dose, etc. . .) 
    (5) Standardized drug nomenclature and instructions for use 
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   vi) Training 
    (1) Physicians 
    (2) Pharmacists 
    (3) Pharmacists Technician 
   vii) Software Uniformity 
    (1) Similar Alerts and Warnings 
    (2) Similar construction of the software 
    (3) Reasonable Safety Measures Implemented 
    (4) Standardized drug names and terms 
   viii) Requirements of written prescriptions removed. Paperless system 
  c)  §3 Security Measures 
   i) Two-factor authentication 
    (1) Password 
    (2) Hard Token 
    (3) Biometrics 
   ii) Agent of Prescriber 
    (1) Can agents assist in prescriptions (only ministerial duties) 
   iii) Software and technology measures (ascertained/unascertained) 
    (1) Valid eSignature 
    (2) What is a signature 
  d) §4 Recordkeeping 
   i) Monthly Logs 
   ii) Maintaining Records 
   iii) Record storage 
  e) §5 Feedback Measures 
   i) Insurance, physician, and pharmacist’s feedback loop 
   ii) What are the required functions and connectivity that must be 
incorporated 
  f) §6 Privacy Concerns, Safe Harbors, Tax Incentives 
   i) Addressing HIPAA and state privacy laws 
   ii) Access to data 
  iii) Verification and validation either through the DEA or other State 
agency 
   iv) Modification and Amendments to State Anti-kickback laws 
  g) §7 Emergency Measures 
   i) Emergency prescription uses 
   ii) Long Term Care, Hospice 
   iii) Public Health emergencies 
  h) §8 Penalties and Remedies 
   i) Criminal Offense for diversion 
   ii) Inappropriate billing (fraud) 
   iii) Medical malpractice, tort issues 
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Model language would need to address conflicting definitions while 
leaving ambiguity for changing prescribing practices and innovative health 
technology.  For example, language should address but not limit the scope 
of computer transmissions, PDA or mobile e-prescribing, and physician 
agent transactions.  Model language should encompass all forms of 
prescribers, such as physicians, dentists, nurse practitioners, optometrists, 
and pharmacists with collaborative practice agreements.  To encompass all 
of the ascertained and unascertained stakeholders, any type of model 
language should be flexible to unforeseen changes in the healthcare 
landscape; for example, the advent of new prescribing professionals.  
Beyond the overall intention of proposed model language, the definitions, 
terms, or technological assertions should be given specific meaning.  For 
example, the term “electronic transmission” has a different meaning in 
Iowa230 than it does in West Virginia.231 
When attempting to draft uniform laws, drafters must respect non-
adoption by the states. Any uniform law must walk the fine line between all-
encompassing versus uselessly ambiguous language.  Giving substantial 
meaning to terms and language must be considered at all possible avenues.  
There is a significant danger for model language to become un-
manageable if states need to qualify or add statutory clauses.  Ambiguous 
model language would just require states to do more work to clarify, guide, 
and coax stakeholders into implementing e-prescribing. 
Model language could also encompass and override conflicting 
regulations and state codes.232  Allowing state legislatures to pass a law that 
removes conflicting regulations in their own state would add significant 
consistency within a single state.  If the model language were to gain 
widespread adoption it would also benefit those health care entities that 
reach beyond one or two states.  Uniformity amongst the states could 
increase e-prescribing transactions and increase companies reach from a 
regional to a national level.  Giving states the tools required to pass 
comprehensive rules would allow clarification for state regulators, 
 
 230. IOWA ADMIN. CODE r. 657-21.1 (2009). 
 231. “‘E-prescribing’ means the transmission, using electronic media, of prescription or 
prescription-related information between a practitioner, pharmacist, pharmacy benefit 
manager or health plan as defined in 45 C.F.R. § 160.103, either directly or through an 
electronic data intermediary.  E-prescribing includes, but is not limited to, two-way 
transmissions between the point of care and the pharmacist.  E-prescribing may also be 
referenced by the terms ‘electronic prescription’ or ‘electronic order.’”  W. VA. CODE R. § 15-
1-2.1.18 (2009). 
 232. As illustrated in the West Virginia example above, where the statutes seem inconsistent 
with each other and the Board of Pharmacy guidance seems to allow e-prescribing.  W. VA. 
CODE § 30-1-12c(a), (c) (2009). 
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prescribers, management, and other shareholders in public and private 
health care entities. 
A proposed uniform law or regulation would reduce time and effort 
needed by legislators and their aides.233  However, any proposed model 
language should include wide discretion at the state’s agency level 
(professional boards) to maintain and endorse state autonomy in the 
delivery and regulation of health care.  Maintaining the state’s traditional 
power to regulate health care234 will keep intact the core principles between 
federal and state authority.235  Additionally, it should be noted that model 
language would be the jumping-off point of e-prescribing rules.  States may 
be in a better position to tailor any language to their needs after the basic 
underpinnings of e-prescribing are adopted through a uniform law.  If a 
state requires additional protective measures the uniform law should not 
discourage customization.  However, it would behoove drafters to think of 
issues and potential solutions prior to a state’s individual adoption of any 
uniform law.  Uniform law adoption is rarely universal.  Many states will 
change or alter certain clauses for the benefit of their specific situation, but if 
model language can set base-line understandings and definitions it will have 
assisted in e-prescribing adoption. 
The next steps to increase the adoption of e-prescribing of controlled 
substances should be to establish a taskforce with the all of the major 
stakeholders at the drafting table (Appendix A).  The taskforce should 
include groups from payors, providers, patient groups, regulators, and other 
third-party intermediaries with an emphasis on unbiased drafting that could 
result in adoption by a majority of the states.  Enlisting a taskforce of state 
regulators, healthcare parties, and patient advocacy groups seems like a 
monumental task.  But so are the savings and benefits that e-prescribing can 
bring the health care delivery system. 
VI.  CONCLUSION 
States, private health care entities and providers will shoulder the burden 
when it comes to implementation of e-prescribing on a large scale.  Model 
language or a set of standards may accommodate and encourage rapid 
adoption of e-prescribing.  Additionally model language resolves many 
unaddressed issues including regulatory inconsistency, diversion and 
privacy.  With the implementation of model language much of the burden 
 
 233. Economic Analysis, supra note 222, at 140. 
 234. See, e.g., NAT’L GOVERNORS ASS’N, supra note 10, at 8-10 (illustrating the various e-
prescribing initiatives); see also Electronic Prescriptions for Controlled Substances, 75 Fed. 
Reg. 16,236, 16,304 (proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 
1304, 1306, 1311). 
 235. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,304. 
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can be taken off of the state and given to stakeholders and those who are 
affected by the implementation of e-prescribing.  E-prescribing has 
enormous potential to save lives, money, and time so patients, providers, 
and payors can benefit. 
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APPENDIX A. LIST OF POTENTIAL STAKE HOLDERS 
Providers 
Pharmacy Chain Representatives (e.g. Walgreens, CVS, Wal-Mart) 
Community Pharmacy Owners 
Staff Pharmacists 
Family Practice Physicians and Other Physician Groups 
Internal Medicine Physicians 
Hospitals 
Small, Rural Hospitals 
Long-Term Care Facilities 
Nurses 
Special Interest Groups 
American Pharmacist Association 
American Medical Association 
National Association of Board of Pharmacy (representing State Board of 
Pharmacy) 
Institute of Medicine 
National Association of Chain Drug Stores 
National Community Pharmacists Association 
American Hospital Association 
Health Care Information and Management Systems Society 
American Insurance Association 
National Association of Insurance Commissioners 
American Health Information Management Association 
National Governors Association 
National Rural Health Association 
Third Party Payors and Intermediaries 
Insurance Companies (Blue Cross Blue Shield, WellPoint) 
SureScripts 
AllScripts 
Software Developers 
Government Regulators 
Center for Medicare and Medicaid Services 
Drug Enforcement Administration 
Office of the National Coordinator for Health Information Technology 
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Patient Advocacy Groups 
Patient Advocacy Foundation 
American Association of Retired Persons 
Privacy Rights Clearinghouse 
Electronic Privacy Information Center 
 
